Patent Grant
12031128
The disclosure relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screening of drug delivery nanoparticles.
Genetic medicines (including gene therapy, gene silencing, splicing regulators, and nuclease based gene editors) are poised to produce revolutionary treatments, including vaccines, infectious disease treatments, antimicrobial treatments, antiviral treatments, and most notably, genetic disease treatments. However, the in vivo delivery of these genetic medicine payloads to the specific tissues and cells that need to be treated, while avoiding tissues and cells that can reduce the efficacy or safety of the genetic medicine, poses a significant challenge. Additional challenges include the ability to deliver large genetic payloads or multiple payloads. Adeno-associated viruses (AAVs) are the most widely used tool for genetic medicine delivery, but AAVs are not able to deliver large genetic payloads or multiple payloads (such as the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system), and they sometimes trigger unwanted immune responses, including the generation of anti-AAV antibodies, a cell mediated response. Some of the immune responses caused by AAV in patients are potentially fatal immune responses.
Therapeutics based on the CRISPR/Cas9 system have an exceptional potential to treat a number of genetic diseases due to the capability of this system for precise and programmable gene editing. Gene editing and repair using the CRISPR/Cas9 system has two main mechanisms, including non-homologous end joining (NHEJ) which repairs the site of cut by inducing random indel mutation, and homology-directed repair (HDR), which repairs the cut site based on a pre-existing template. Because a pre-designed template can be used for HDR-directed repair, therapies based on this mechanism can be tailored to cure a large number of different genetic diseases. However, the main challenge is that HDR repair requires the delivery of CRISPR/Cas9, small guide RNA (sgRNA) and a donor DNA strand at the same time to a particular location. This requirement becomes particularly limiting for in vivo applications because ensuring co-delivery of multiple large molecules to the same targeted location is currently not feasible. For example, the Cas9 enzyme sequence and guide RNA complex is too large to fit into AAVs.
Thus, there is a need for effective non-viral delivery systems, including gene delivery systems. The current state-of-the-art non-viral gene delivery systems, such as liposomes, have many drawbacks such as poor biocompatibility and the inability to easily engineer or functionalize them. Additional concerns are that such non-viral gene delivery systems are easily degraded by various enzymes as they pass through intracellular or intercellular compartments, and these systems have not been able to package multiple large payloads.
The inventors have designed barcoded polymer nanoparticle (e.g., a polymer derived from a controlled living/radical polymerization such as a RAFT polymer) delivery compositions. These compositions have the advantage of being biocompatible, non-toxic, and can be programmed in many ways. For example, the barcoded polymer nanoparticle delivery compositions can be programmed to have functional groups that enable them to evade early degradation, that enable them to evade immune responses, and that enable intracellular imaging and controlled delivery of therapeutic genes and other therapeutic molecules. Thus, these non-viral delivery compositions can enhance the stability, safety, and/or efficacy of genetic medicine payloads and other payloads by providing immune evasion, tissue-directed intracellular delivery, and the ability to deliver large genetic payloads or multiple payloads.
The present disclosure combines these non-viral delivery compositions with rapid design, build, test, and learn (DBTL) technologies that will vastly accelerate gene delivery and address the disadvantages that exist in limited gene delivery vehicles. In addition to hastening editing therapies of today to transition through clinicals, it is anticipated that these technologies will enable the general delivery of larger more molecularly diverse genetic payloads, and other payloads, which will in turn, continue to improve treatments for genetic diseases and other diseases.
In some aspects, the disclosure provides for a composition comprising a non-viral delivery vehicle comprising one or more nanoparticle forming polymers, and a nucleic acid construct.
In some aspects, the disclosure provides for a method of in vivo screening for a desired polymer nanoparticle for use as a delivery vehicle, the method comprising (a) preparing a library comprising two or more types of polymer nanoparticles, wherein each polymer nanoparticle is associated with a nucleic acid construct comprising a different polynucleotide barcode, (b) administering the library to an animal, (c) removing cells or tissues from the animal, (d) isolating the nucleic acid constructs from the cells or the tissues of the animal, (e) detecting the nucleic acid constructs in the cells or the tissues of the animal, and (f) identifying the desired polymer nanoparticle for use as a delivery vehicle.
In some aspects, the disclosure provides for a method of treating a patient with a disease, the method comprising administering to the patient the polymer nanoparticle identified in the in vivo screening methods described herein, wherein the polymer nanoparticle further comprises a drug payload, such as a polynucleotide or a protein payload or a small molecule therapeutic payload, and treating the disease in the patient.
The following clauses, and combinations thereof, provide various additional illustrative aspects of the invention described herein. The various embodiments described in any other section of this patent application, including the section titled “DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS” and the “EXAMPLES” are applicable to any of the following embodiments of the invention described in the numbered clauses below.
1. A composition comprising:
2. The composition of clause 1, wherein the non-viral delivery vehicle comprises a polymer nanoparticle.
3. The composition of clause 1 or 2, wherein the nucleic acid construct is associated with the non-viral delivery vehicle via an electrostatic interaction.
4. The composition of any one of clauses 1 to 3, wherein the nucleic acid construct is associated with the non-viral delivery vehicle by an electrostatic interaction of a positively charged polymer segment of the one or more nanoparticle forming polymers and a negatively charged polynucleotide segment of the nucleic acid construct.
5. The composition of any one of clauses 1 to 3, wherein the nucleic acid construct is associated with the non-viral delivery vehicle by a high affinity, non-covalent bond interaction between a biotin molecule on the 5′ and/or the 3′ end of the nucleic acid construct and a molecule that binds to biotin on the one or more nanoparticle forming polymers.
6. The composition of any one of clauses 1 to 3, wherein the nucleic acid construct is associated with the non-viral delivery vehicle by a covalent bond between a carboxy terminated polymer segment and the nucleic acid construct, wherein the nucleic acid construct comprises a primary amine on the 5′ and/or the 3′ end.
7. The composition of any one of the preceding clauses, wherein the nucleic acid construct comprises:
8. The composition of clause 7, wherein the primer binding segments range in length from about 15 base pairs to about 30 base pairs.
9. The composition of clause 7 or 8, wherein the primer binding segments are a universal primer binding set.
10. The composition of any one of clauses 7 to 9, wherein the one or more polynucleotide barcodes comprise unique sequences of 6-20 nucleotides in length.
11. The composition of clause 10, wherein the polynucleotide barcodes further comprise a hamming distance of at least 2-6 bases between any two unique polynucleotide barcode sequences.
12. The composition of any one of the preceding clauses, wherein the nucleic acid construct further comprises from about 6 to about 12 random bases at the 3′ end of the polynucleotide barcode.
13. The composition of clause 12, wherein the about 6 to about 12 random bases at the 3′ end of the polynucleotide barcode are for bioinformatic removal of PCR duplicates.
14. The composition of any one of the preceding clauses, wherein the nucleic acid construct ranges in length from about 42 nucleotides to about 210 nucleotides.
15. The composition of any one of the preceding clauses, wherein the one or more nanoparticle forming polymers comprise monomer units compatible with a controlled living/radical polymerization.
16. The composition of any one of the preceding clauses, wherein the one or more nanoparticle forming polymers are prepared by reversible-deactivation radical polymerization, atom transfer radical polymerization (ATRP), reversible addition fragmentation chain transfer polymerization (RAFT), iodine-transfer polymerization (ITP), selenium-centered radical-mediated polymerization, telluride-mediated polymerization (TERP), stibine-mediated polymerization, or ring-opening polymerization.
17. The composition of any one of the preceding clauses, wherein the one or more nanoparticle forming polymers are prepared from monomers containing a vinyl group.
18. The composition of any one of the preceding clauses, wherein the one or more nanoparticle forming polymers are prepared using a chain transfer agent such as those used in reversible addition-fragmentation chain transfer (RAFT).
19. The composition of any one of the preceding clauses, wherein the one or more nanoparticle forming polymers are RAFT block copolymers comprising
20. The composition of clause 19, wherein the non-viral delivery vehicle has one or more of an overall molecular weight (Mn) in the range of about 25 kDa to about 60 kDa, an overall degree of polymerization in the range of about 700 to about 900, a target size in the range of about of about 10 to about 60 nm, and a maximum corona-to-core ratio (CCR) of about 1.5 to about 3.5.
21. The composition of clause 19 or 20, wherein the first block is prepared from one or more monomer units selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
22. The composition of clause 19 or 20, wherein the first block is prepared from one of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, or methyl methacrylate.
23. The composition of any one of clauses 19 to 22, wherein the second block is prepared from one or more monomer units selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
24. The composition of any one of clauses 19 to 23, wherein the second block is a random copolymer prepared from two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate. and methyl methacrylate.
25. The composition of any one of clauses 19 to 23, wherein the second block is a random copolymer prepared from three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate.
26. The composition of any one of clauses 19 to 25, wherein the second block is a random copolymer prepared from 2-dimethylaminoethyl acrylate, butyl methacrylate, and propyl acrylic acid; or 2-dimethylaminoethyl acrylate and butyl methacrylate; or 2-dimethylaminoethyl acrylate, butyl methacrylate, and ethyl acrylic acid.
27. The composition of any one of clauses 19 to 26, wherein each chain transfer agent is independently selected from the group consisting of bis(carboxymethyl)trithiocarbonate, bis(2-amino-2-oxoethyl) trithiocarbonate, bis[4-(2-hydroxyethoxycarbonyl)benzyl] trithiocarbonate, 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylventanoic acid, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid, and 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid.
28. The composition of any one of clauses 19 to 27, wherein the first capping unit is of the formula
wherein * represents a point of covalent attachment to the first block.
29. The composition of any one of clauses 19 to 28, wherein the second capping unit is of the formula
wherein * represents a point of covalent attachment to the second block, and R is —SC2-C12 alkyl or C6H5,
30. A method of in vivo screening for a desired polymer nanoparticle for use as a delivery vehicle, the method comprising (a) preparing a library comprising two or more types of polymer nanoparticles, wherein each polymer nanoparticle is associated with a nucleic acid construct comprising a different polynucleotide barcode, (b) administering the library to an animal, (c) removing cells or tissues from the animal, (d) isolating the nucleic acid constructs from the cells or the tissues of the animal, (e) detecting the nucleic acid constructs in the cells or the tissues of the animal, and (f) identifying the desired polymer nanoparticle for use as a delivery vehicle.
31. The method of clause 30 wherein the polymer nanoparticle associated with the nucleic acid construct is according to any one of clauses 1 to 29.
32. The method of clause 30 or 31 wherein the nucleic acid construct is detected by a method selected from the group consisting of the polymerase chain reaction (PCR), isothermal amplification, sequencing, or a combination thereof, to obtain nucleotide sequence data.
33. The method of any one of clauses 30 to 32, wherein the polymer nanoparticle is loaded with a payload.
34. The method of clause 33, wherein the payload is a luminescent molecule.
35. The method of clause 34, wherein the luminescence is used to track the biodistribution or cell uptake via imaging.
36. The method of any one of clauses 30 to 35, wherein the administration to the animal is via an intramuscular, an intravenous, an intraperitoneal, an oral, or a pulmonary route.
37. The method of any one of clauses 30 to 36, wherein the nucleic acid construct is isolated from the cells and the tissues by mixing with a first organic compound and incubating the organic phase with an aqueous phase of the cell or tissue sample, separating the organic phase from the aqueous phase, mixing the organic phase with a second organic compound, incubating the mixture, precipitating the nucleic acid construct from the mixture, removing the organic phase by evaporation, and resuspending the nucleic acid construct in an aqueous composition.
38. The method of clause 37, wherein the organic phase comprises phenol chloroform.
39. The method of clause 37, wherein the nucleic acid construct is separated from cationic material in the cells or tissues by titrating the aqueous composition of the nucleic acid construct to a pH of greater than 7.4.
40. The method of clause 30, wherein the nucleic acid construct is separated from material in the cells or tissues by binding the nucleic acid construct with a molecule with a binding affinity to the nucleic acid construct greater than the binding affinity to the cell or tissue material.
41. The method of clause 30, wherein the nucleic acid construct is separated from material in the cells or tissues via size exclusion chromatography.
42. The method of clause 30, wherein the nucleic acid construct is separated from material in the cells or tissues via dialysis or diafiltration.
43. The method of clause 30, wherein the nucleic acid construct is separated from material in the cells or tissues via filtration.
44. The method of clause 30, wherein the nucleic acid construct is separated from material in the cells or tissues by digesting proteins using an enzyme.
45. The method of clause 44 wherein the enzyme is Proteinase K.
46. The method of clause 30, wherein the nucleic acid constructs associated with the polymer nanoparticles are detected by first diluting the isolated nucleic acid constructs by a factor of at least 1000 times, and then amplifying the nucleic acid constructs by PCR using primers.
47. The method of clause 46, wherein the primers from the PCR step are enzymatically digested prior to detection of amplicons.
48. The method of clause 32, wherein the nucleotide sequence data is converted to fast Q files; and the fast Q files are mapped to known polynucleotide barcodes and the polynucleotide barcodes are enumerated.
49. A method of treating a patient with a disease, the method comprising administering to the patient the polymer nanoparticle identified in the in vivo screening method of any one of clauses 30 to 48, wherein the polymer nanoparticle further comprises a payload, and treating the disease in the patient.
The invention relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as a controlled living/radical polymerization products, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screening of drug delivery nanoparticles. In one embodiment, the payload can be a nucleic acid of 3 kB or more, or any other suitable payload, such as another polynucleotide or a protein or a small molecule therapeutic or a luminescent molecule.
The invention relates to the use of barcoded polymer nanoparticle compositions (e.g., a polymer nanoparticle derived from a controlled living/radical polymerization process, such as RAFT copolymers) as a platform with a high degree of tunability in structure and function, opportunities to protect payloads from adverse reactions or degradation by the immune system, and passive cell targeting via surface charge, or particle size. These delivery systems also lend themselves to computer-aided design, and they have suitable pathways to robust, commercial scale manufacturing processes with higher yields and fewer purification steps than viral delivery composition manufacturing processes.
In one embodiment a composition comprising a polymer nanoparticle (e.g., a polymer nanoparticle derived from a controlled living/radical polymerization process, such as RAFT polymer) associated with a nucleic acid construct is provided. In another embodiment, a method of in vivo screening to identity a desired polymer nanoparticle (e.g., a polymer nanoparticle derived from a controlled living/radical polymerization process, such as RAFT polymer) associated with a nucleic acid construct for use as a delivery vehicle is provided. In another embodiment, a method of treating a patient with a disease is provided comprising administering to the patient the polymer nanoparticle identified in the screening method.
In one embodiment, the method of in vivo screening for a desired polymer nanoparticle for use as a delivery vehicle comprises, (a) preparing a library comprising two or more types of polymer nanoparticles, wherein each polymer nanoparticle is associated with a nucleic acid construct comprising a different polynucleotide barcode, (b) administering the library to an animal, (c) removing cells or tissues from the animal, (d) isolating the nucleic acid constructs from the cells or tissues of the animal, (e) detecting the nucleic acid constructs in the cells or tissue of the animal, and (f) identifying the desired polymer nanoparticle for use as a delivery vehicle. In various embodiments, the nucleic acid construct can be detected by, for example, the polymerase chain reaction (PCR), isothermal amplification, or sequencing the nucleic acids in the cells or tissues of the animal.
In another embodiment, a method of treating a patient with a disease is provided, comprising administering to the patient the polymer nanoparticle identified in the in vivo screening method, wherein the polymer nanoparticle further comprises a drug payload, such as a polynucleotide or a protein payload, or a small molecule therapeutic or luminescent molecule payload, and treating the disease in the patient.
In various embodiments, any suitable route for administration of the library of polymer nanoparticles associated with nucleic acid constructs for the method of in vivo screening for the polymer nanoparticle associated with a nucleic acid construct, or for the method of treatment can be used including parenteral administration. Suitable routes for such parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, epidural, intracerebroventricular, intraurethral, intrasternal, intracranial, intratumoral, intramuscular and subcutaneous delivery. In one embodiment, means for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques. In other embodiments, oral or pulmonary routes of administration can be used.
In one aspect, libraries of barcoded polymer nanoparticles can be pooled and concentrated before administration to the animal of the nucleic acid constructs associated with the polymer nanoparticles. Methods for library preparation and for sequencing are described in Green and Sambrook, “Molecular Cloning: A Laboratory Manual”, 4th Edition, Cold Spring Harbor Laboratory Press, (2012), incorporated herein by reference.
In various embodiments, cell or tissue samples may be analyzed for the presence of the polymer nanoparticle associated with the nucleic acid constructs described herein. The samples can be any tissue, cell, or fluid sample from an animal, for example, selected from the group consisting of urine, nasal secretions, nasal washes, inner ear fluids, bronchial lavages, bronchial washes, alveolar lavages, spinal fluid, bone marrow aspirates, sputum, pleural fluids, synovial fluids, pericardial fluids, peritoneal fluids, saliva, tears, gastric secretions, stool, reproductive tract secretions, lymph fluid, whole blood, serum, plasma, or any tissue or cell sample from an animal. Exemplary tissue or cell samples include brain tissue or cells, muscle tissue or cells, skin tissue or cells, heart tissue or cells, kidney tissue or cells, stomach tissue or cells, liver tissue or cells, urinary tract tissue or cells, gastrointestinal tract tissue or cells, head or neck tissue or cells, lung tissue or cells, reproductive tract tissue or cells, pancreatic tissue or cells, or any other tissue or cell type from an animal.
In one illustrative aspect for removing cells or tissues from the animal and isolating the nucleic acid constructs from the cells or tissues of the animal, the nucleic acid constructs are removed from cells or tissues of the animal. In various embodiments, nucleic acid constructs (e.g., DNA or RNA) obtained from the tissues or cells of the animal can be removed by rupturing the cells and isolating the nucleic acid constructs from the lysate. Techniques for rupturing cells and for isolation of nucleic acids are well-known in the art, and removal techniques include homogenization, such as by using a bead-beating technique. In other embodiments, the nucleic acid constructs may be isolated by rupturing cells using a detergent or a solvent, such as phenol-chloroform. In another aspect, the nucleic acid constructs may be separated from the lysate by physical methods including, but not limited to, centrifugation, dialysis, diafiltration, filtration, size exclusion, pressure techniques, digestion of proteins with Proteinase K, or by using a substance with an affinity for nucleic acids such as, for example, beads that bind nucleic acids.
In one illustrative embodiment, the nucleic acid constructs are removed from cells or tissues by treating with a mixture of an organic phase (e.g., phenol chloroform) and an aqueous phase (e.g., water). The organic phase (e.g., phenol chloroform) is isolated and the nucleic acid construct can be precipitated by raising the pH, for example, to pH 7.4. The organic phase (e.g., phenol chloroform) can be evaporated and the nucleic acid constructs can be suspended in water and diluted to appropriate concentrations for PCR and/or sequencing. In one embodiment, the isolated nucleic acid constructs are suspended in either water or a buffer after sufficient washing.
In other embodiments, commercial kits are available for isolation of the nucleic acid constructs, such as Qiagen™, Nuclisensm™, Wizard™ (Promega), QiaAmp 96 DNA Extraction Kit™ and a Qiacube HT™ instrument, and Promegam™. Methods for preparing nucleic acids for PCR and/or sequencing are also described in Green and Sambrook, “Molecular Cloning: A Laboratory Manual”, 4th Edition, Cold Spring Harbor Laboratory Press, (2012), incorporated herein by reference.
The polynucleotide barcodes can be detected by using, for example, the polymerase chain reaction (PCR), isothermic amplification, sequencing, and/or imaging. The polymerase chain reaction (PCR) has been developed to analyze nucleic acids in a laboratory. PCR evolved over the last decade into a new generation of devices and methods known as Next Generation Sequencing (NGS). NGS provides faster detection and amplification of nucleic acids at a cheaper price. The NGS devices and methods allow for rapid sequencing as the nucleic acids are amplified in massively parallel, high-throughput platforms.
In one illustrative aspect, the nucleic acid constructs can be sequenced, to detect the polynucleotide barcodes using any suitable sequencing method including Next Generation Sequencing (e.g., using Illumina, ThermoFisher, or PacBio or Oxford Nanopore Technologies sequencing platforms), sequencing by synthesis, pyrosequencing, nanopore sequencing, or modifications or combinations thereof can be used. In one embodiment, the sequencing can be amplicon sequencing. In another embodiment, the sequencing can be whole genome sequencing. In another embodiment, the sequencing can be exome/targeted hybridization sequencing. Methods for sequencing nucleic acids are also well-known in the art and are described in Sambrook et al., “Molecular Cloning: A Laboratory Manual”, Cold Spring Harbor Laboratory Press, incorporated herein by reference.
In one aspect, the nucleic acid construct can comprise a polynucleotide barcode and the barcode comprises a unique sequence not present in any known genome for identification of the polynucleotide barcode. In another embodiment, a set of different nucleic acid constructs with different polynucleotide barcodes (e.g., 88 or 96 different polynucleotide barcodes) can be used to allow for multiplexing of samples on one sequencing run.
In various embodiments, the polynucleotide barcodes can be from about 5 to about 35 base pairs in length, about 5 to about 34 base pairs in length, about 5 to about 33 base pairs in length, about 5 to about 32 base pairs in length, about 5 to about 31 base pairs in length, about 5 to about 30 base pairs in length, about 5 to about 29 base pairs in length, about 5 to about 28 base pairs in length, about 5 to about 27 base pairs in length, about 5 to about 26 base pairs in length, about 5 to about 25 base pairs in length, about 5 to about 24 base pairs in length, about 5 to about 23 base pairs in length, about 5 to about 22 base pairs in length, about 5 to about 21 base pairs in length, about 5 to about 20 base pairs in length, about 5 to about 19 base pairs in length, about 5 to about 18 base pairs in length, about 5 to about 17 base pairs in length, about 5 to about 16 base pairs in length, about 5 to about 15 base pairs in length, about 5 to 14 base pairs in length, about 5 to 13 base pairs in length, about 5 to 12 base pairs in length, about 5 to 11 base pairs in length, about 5 to 10 base pairs in length, about 5 to 9 base pairs in length, about 5 to 8 base pairs in length, about 6 to 10 base pairs in length, about 7 to 10 base pairs in length, about 8 to 10 base pairs in length, or about 6 to about 20 base pairs in length.
Various embodiments of polynucleotide barcodes are shown below in Table 1 (labeled “Polynucleotide Barcodes”). These polynucleotide barcodes can be used in the nucleic acid constructs alone or in combinations of, for example, two or more polynucleotide barcodes, three or more polynucleotide barcodes, four or more polynucleotide barcodes, etc. In the embodiment where more than one polynucleotide barcode is used, the hamming distance between the polynucleotide barcodes can be about 2 to about 6 nucleotides, or any suitable number of nucleotides can form a hamming distance, or no nucleotides are present between the polynucleotide barcodes.
In another embodiment, a random sequence fragment can be linked to the 5′ and/or the 3′ end of the polynucleotide barcode and the random sequence fragment can, for example, be used for bioinformatic removal of PCR duplicates. The random sequence fragment can also be used to add length to the nucleic acid construct and can serve as a marker for bioinformatic analysis to identify the beginning or the end of the polynucleotide barcode after sequencing. In another embodiment, the nucleic acid construct comprises at least a first and a second random sequence fragment, and the first random sequence fragment can be linked to the 5′ end of the polynucleotide barcode and the second random sequence fragment can be linked to the 3′ end of the polynucleotide barcode. In another embodiment, one or at least one random sequence fragment is linked to the 5′ and/or the 3′ end of the polynucleotide barcode. In one aspect, the random sequence fragments can be extended as needed to make the nucleic acid construct longer for different applications such as whole genome sequencing where short inserts may be lost.
In various embodiments, the random sequence fragments can be from about 5 to about 20 base pairs in length, about 5 to about 19 base pairs in length, about 5 to about 18 base pairs in length, about 5 to about 17 base pairs in length, about 5 to about 16 base pairs in length, about 5 to about 15 base pairs in length, about 5 to about 14 base pairs in length, about 5 to about 13 base pairs in length, about 5 to about 12 base pairs in length, about 5 to about 11 base pairs in length, about 5 to about 10 base pairs in length, about 5 to about 9 base pairs in length, about 5 to about 8 base pairs in length, about 6 to about 10 base pairs in length, about 7 to about 10 base pairs in length, or about 8 to about 10 base pairs in length.
In another illustrative aspect, the polynucleotide barcode may be flanked by primer binding segments (i.e., directly or indirectly linked to the polynucleotide barcode) so that the nucleic acid construct comprising the polynucleotide barcode can be amplified during a polymerase chain reaction (PCR) and/or sequencing protocol. In one aspect, the primer binding segments can be useful for binding to one or more universal primers or a universal primer set. In one illustrative embodiment, the universal primers can contain overhang sequences that enable attachment of index adapters for sequencing. In this aspect, the primers can be any primers of interest. In this embodiment, the first primer binding segment can be linked at its 3′ end to the 5′ end of a first random sequence fragment and the second primer binding segment can be linked at its 5′ end to the 3′ end of a second random sequence fragment with the polynucleotide barcode between the random sequence fragments. In another embodiment, the first primer binding segment can be linked at its 3′ end to the 5′ end of the polynucleotide barcode and the second primer binding segment can be linked at its 5′ end to the 3′ end of a random sequence fragment (see
In embodiments where primer binding segments are included in the nucleic acid construct, the primer binding segments can range in length from about 15 base pairs to about 30, from about 15 base pairs to about 29 base pairs, from about 15 base pairs to about 28 base pairs, from about 15 base pairs to about 26 base pairs, from about 15 base pairs to about 24 base pairs, from about 15 base pairs to about 22 base pairs, from about 15 base pairs to about 20 base pairs, 16 base pairs to about 28 base pairs, from about 16 base pairs to about 26 base pairs, from about 16 base pairs to about 24 base pairs, from about 16 base pairs to about 22 base pairs, from about 16 base pairs to about 20 base pairs, 17 base pairs to about 28 base pairs, from about 17 base pairs to about 26 base pairs, from about 17 base pairs to about 24 base pairs, from about 17 base pairs to about 22 base pairs, from about 17 base pairs to about 20 base pairs, 18 base pairs to about 28 base pairs, from about 18 base pairs to about 26 base pairs, from about 18 base pairs to about 24 base pairs, from about 18 base pairs to about 22 base pairs, or from about 18 base pairs to about 20 base pairs.
An exemplary sequence of a nucleic acid construct is shown below. The /5AmMC6/ is a 5′ amine modification for attachment to the polymer nanoparticle. The *'s are phosphorothioate bond modifications for stability. The A*G*A*CGTGTGCTCTTCCGATCT (SEQ ID NO: 1001) sequence is the 5′ primer binding segment sequence. The GCTACATAAT (SEQ ID NO: 1) is an exemplary barcode polynucleotide sequence. The N's represent the random sequence fragment. The AGATCGGAAGAGCGTCG*T*G*T (SEQ ID NO: 1002) is the 3′ primer binding segment sequence.
In all of the various embodiments described above, the entire nucleic acid construct can range in length from about 30 base pairs to about 240 base pairs, about 30 base pairs to about 230 base pairs, about 30 base pairs to about 220 base pairs, about 30 base pairs to about 210 base pairs, about 30 base pairs to about 200 base pairs, about 30 base pairs to about 190 base pairs, about 30 base pairs to about 180 base pairs, about 30 base pairs to about 170 base pairs, about 30 base pairs to about 160 base pairs, about 30 base pairs to about 150 base pairs, about 30 base pairs to about 140 base pairs, about 30 base pairs to about 130 base pairs, about 30 base pairs to about 120 base pairs, from about 30 base pairs to about 110 base pairs, from about 30 base pairs to about 100 base pairs, from about 30 base pairs to about 90 base pairs, from about 30 base pairs to about 80 base pairs, from about 30 base pairs to about 70 base pairs, from about 30 base pairs to about 60 base pairs, from about 30 base pairs to about 50 base pairs, from about 30 base pairs to about 40 base pairs, 40 base pairs to about 120 base pairs, from about 40 base pairs to about 110 base pairs, from about 40 base pairs to about 100 base pairs, from about 40 base pairs to about 90 base pairs, from about 40 base pairs to about 80 base pairs, from about 40 base pairs to about 70 base pairs, from about 40 base pairs to about 60 base pairs, from about 40 base pairs to about 50 base pairs, 50 base pairs to about 120 base pairs, from about 50 base pairs to about 110 base pairs, from about 50 base pairs to about 100 base pairs, from about 50 base pairs to about 90 base pairs, from about 50 base pairs to about 80 base pairs, from about 50 base pairs to about 70 base pairs, from about 50 base pairs to about 60 base pairs, or about 42 base pairs to about 210 base pairs.
The nucleic acid constructs are associated with the polymer nanoparticles, and exemplary polymer nanoparticle to nucleic acid construct ratio ranges are about 20:1 to about 10000:1, about 20:1 to about 9000:1, about 20:1 to about 8000:1, about 20:1 to about 7000:1, about 20:1 to about 6000:1, about 20:1 to about 5000:1, about 20:1 to about 4000:1, about 20:1 to about 3000:1, about 20:1 to about 2000:1, about 20:1 to about 1000:1, about 20:1 to about 900:1, about 20:1 to about 800:1, about 20:1 to about 700:1, about 20:1 to about 600:1, about 20:1 to about 500:1, about 20:1 to about 400:1, about 20:1 to about 300:1, about 20:1 to about 200:1, or about 20:1 to about 100:1.
In one illustrative aspect, the barcoded polymer nanoparticles may be used as delivery vehicles according to the present disclosure. In some embodiments, the non-viral delivery vehicle comprises one or more nanoparticle forming polymers. In some embodiments, the non-viral delivery vehicle comprises polymer nanoparticles. In some embodiments, the non-viral delivery vehicle is not a lipid based system. In some embodiments, the non-viral delivery vehicle comprises polymer nanoparticles made from controlled living/radical polymerization processes. It will be appreciated that the identity of the monomer units is not particularly limited so long as the monomer units being used are compatible with a controlled living/radical polymerization, such as reversible-deactivation radical polymerization, atom transfer radical polymerization (ATRP), reversible addition fragmentation chain transfer polymerization (RAFT), iodine-transfer polymerization (ITP), selenium-centered radical-mediated polymerization, telluride-mediated polymerization (TERP), stibine-mediated polymerization, ring-opening polymerization, or like polymerization processes. In some embodiments, the polymer nanoparticles may be made by RAFT copolymerization to synthesize a diverse set of block copolymers, and to screen their ability to form complexes with a payload. In one aspect, polymer nanoparticles (e.g., RAFT copolymers) may be produced by chemically bonding a payload to a constituent polymer, such as by the grafting of the payload onto RAFT copolymers using chain transfer agents, and subsequently assembling the polymers into a delivery vehicle.
In various embodiments, payloads may be combined with the polymer nanoparticles compositions using any or all of covalent bonds, electrostatic interactions, and ligand affinity interactions. In one aspect, covalent bonding methods include the use of EDC/NHS to form stable amide bonds between the payload and the polymer nanoparticles for improved stability (both “on the shelf” and in vivo), ease of separation and extraction, and sensitive detection. In another illustrative aspect, electrostatic bonding methods include the use of cationic polymer nanoparticles that electrostatically complex with the payload. In another embodiment, ligand affinity bonding includes the use of ligands such as avidin and biotin, both covalently bonded to the polymer nanoparticles and the payload via EDC/NHS chemistry to yield the stable combination of the payload and the polymer nanoparticles.
It will be appreciated that RAFT polymerization is generally known in the art. Suitable reagents, monomers, and conditions for RAFT polymerization previously investigated can be used in the copolymers, methods, and compositions described herein, such as those described in U.S. Pat. Nos. 9,006,193, 9,464,300, and 9,476,063, the disclosures of each of which are incorporated by reference in their entirety.
Chain transfer agents (CTAs) useful in connection with the present disclosure are known in the art. The identity of the CTA is not particularly limited. It will be appreciated that chain transfers steps that form the basis of RAFT polymerization involve a reversible transfer of a functional chain end-group (typically a thiocarbonylthio group, Z—C(═S)S—R) between chains and the propagating radicals. The overall process is comprised of the insertion of monomers between the R— and Z—C(═S)S-groups of a RAFT agent (CTA), which form the α and ω end-group of the majority of the resulting polymeric chains. Suitable CTAs for use in connection with the present disclosure include but are not limited to trithiocarbonates (Z═S-alkyl), dithiobenzoates (Z═Ph), dithiocarbamate (Z═N-alkyl), xanthates (Z═O-alkyl), and the like. (See, Sébastien Perrier, Macromolecules 2017 50 (19), 7433-7447) In some embodiments, RAFT copolymerization may be achieved using chain transfer agents (CTAs) containing one or more terminal carboxyl groups in order to obtain carboxy terminated polymers with ends available for bonding to the payload via the methods described above. In this embodiment, when the resulting mono or di-carboxy terminated polymer is dispersed in a low pH (e.g., a pH of less than 6) buffer, both ends of the polymer are exposed and available for labeling via EDC/NHS chemistry. In this embodiment, when the polymer is transferred to a physiological pH (˜pH 7), the core blocks self-assemble, encapsulating the payload in the hydrophobic core, to be released and exposed upon acidification in the endosomal compartment of a cell. In some embodiments, the first or second chain transfer agent can be selected from the group consisting of bis(carboxymethyl)trithiocarbonate, bis(2-amino-2-oxoethyl) trithiocarbonate, bis[4-(2-hydroxyethoxycarbonyl)benzyl] trithiocarbonate, 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid, and 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid, 4-cyano-4-(thiobenzoylthio)pentanoic acid, 2-cyano-2-propyl benzodithioate, cyanomethyl methyl(phenyl)carbamodithioate, 2-cyano-2-propyl dodecyl trithiocarbonate, 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid, cyanomethyl dodecyl trithiocarbonate, 2-cyano-2-propyl 4-cyanobenzodithioate, and the like.
It will be apprectiated that RAFT useful in connection with the present disclosure can be of a variety of polymer compositions. For example, RAFT polymers useful in connection with the present disclosure can be a random block polymer comprising a single polymer block, or a diblock RAFT copolymer comprising two polymer blocks, or a triblock RAFT copolymer comprising three polymer blocks, or further numbers of blocks can be used. The skilled person will readily appreciate that the preparation of block polymers by RAFT polymerization is known in the art and that such polymerization processes can be applied to the present disclosure. (See, Goby, et. al., Nat. Commun. 4:2505 doi: 10.1038/ncomms3505 (2013))
In some embodiments, RAFT copolymers as prepared herein can be described by the following structure:
CTACap-[Block 1]m[Block 2]n-CTACap
where each CTACap is a capping unit derived from the chain transfer agent(s) used in the process for preparing the RAFT copolymer. The CTA used for preparing each of Block 1 and Block 2 can be the same or different. In some embodiments, the CTA used to prepare each of Block 1 and Block 2 is the same (e.g. macroCTA). In some embodiments, the CTA used to prepare each of Block 1 and Block 2 is different. In some embodiments, the CTA used to prepare one or both of Block 1 and Block 2 comprises a functional group for the covalent attachment of a biomolecule, drug, or label to the RAFT copolymer. In some embodiments, the covalent attachment can be via an ester or an amide bond. In some embodiments, the covalent attachment can be via EDC-NHS chemistry. In some embodiments, the first capping unit is of the formula
wherein * represents a point of covalent attachment to the first block. In some embodiments, the second capping unit is of the formula
wherein * represents a point of covalent attachment to the second block, and R is —SC2-C12 alkyl or C6H5,
In some embodiments, the RAFT copolymer can be associated with a DNA molecule, in particular a nucleic acid construct of the present disclosure, via several methods including, electrostatic interaction, high affinity, non-covalent bond, avidin-streptavidin conjugation, or by direct covalent attachment through, for example, an amide bond. In some embodiments, the RAFT copolymer can be associated with a DNA molecule, in particular a nucleic acid construct of the present disclosure, via electrostatic interaction complexed with a biological molecule. In some embodiments, the RAFT copolymer can be associated with a DNA molecule, in particular a nucleic acid construct of the present disclosure, via electrostatic interaction complexed with a biological molecule. In some embodiments, the RAFT copolymer can be associated with a DNA molecule, in particular a nucleic acid construct of the present disclosure, via a high affinity, non-covalent bond, avidin-streptavidin conjugation. In some embodiments, the RAFT copolymer can be associated with a DNA molecule, in particular a nucleic acid construct of the present disclosure, by direct covalent attachment through, for example, an amide bond.
As shown in
In some embodiments, each of Block 1 and Block 2 can comprise one or more monomer units polymerized using a RAFT polymerization process. It will be appreciated that the identity of the monomer units is not particularly limited so long as the monomer units being used are compatible with a controlled living/radical polymerization, such as reversible-deactivation radical polymerization, atom transfer radical polymerization (ATRP), reversible addition fragmentation chain transfer polymerization (RAFT), iodine-transfer polymerization (ITP), selenium-centered radical-mediated polymerization, telluride-mediated polymerization (TERP), stibine-mediated polymerization, ring-opening polymerization, or like polymerization processes. Suitable monomer units include but are not limited to 2-dimethylaminoethyl acrylate (DMAEMA), 2-(diethylamino) ethyl methacrylate (DEAEMA), 2-(diisopropylamino) ethyl methacrylate (DPAEMA), butyl methacrylate (BMA), ethyl acrylic acid (EAA), propyl acrylic acid (PAA), (hydroxyethyl)methacrylate (HEMA), methyl methacrylate (MMA), Acrylic acid (AA), Acetoacetanilide (AAA), 4-Aminobenzonitrile (ABN), 9-Anthracenylmethyl acrylate (ACMA), 9-Anthracenylmethyl methacrylate (ACMMA), Aminoethyl methacrylate (AEM), 2-(2-aminoethylamino) ethyl methacrylate (AEAEMA), 4-(2-Acryloxyethoxy)-2-hydroxybenzophenone (AEHBP), 2-Aminoethyl methacrylate (AEMA), N-(2-Aminoethyl) methacrylamide (AEMAA), 3-amino-2-hydroxypropyl methacrylate (AEAHPMA), 3-aminopropyl methacrylamide (AHPMA), Allyl methacrylate (ALMA), Acrylamide (AM), Amidoamine (AMA), 3-Methacryl amido-3-methylbutanoic acid (AMBA), 2-Allyloxybenzaldehyde (AOBA), [2-(Acryloyloxy)ethyl]trimethylammonium chloride (AOETMA), 3-(Acryloyloxy)-2-hydroxypropyl methacrylate (AOHOPMA), 4-Aminophenethyl alcohol (APA), N-(3-Aminopropyl)methacrylamide (APMA), 5-(3-(Amino)-propoxy)-2-nitrobenzyl methacrylate (APNBMA), N—[N′-(2-aminoethyl)-2-aminoethyl]aspartamide (Asp(DET)), 2-Azidoethyl Methacrylate (AzEMA), 2,2′-Bithiophene (2-2-BTP), tert-Butyl acrylate (BA), Bromoacetaldehyde diethyl acetal (BAADA), N-(t-BOC-aminopropyl)methacrylamide (BAPMAA), tert-Butyl 2-bromoacrylate (BBA), 4-Butylbenzoyl chloride (BBC), 1,3-Butadiene (BD), 2-Butyl-2-ethyl-1,3-propanediol (BEPD), Di-tert-butyl iminodiacetate (BIDA), 3-(Bromomethyl)-5-((trimethylsilyl)ethynyl)benzenesulfonyl fluoride (BMTMSEBS), 2-(Benzyloxy)ethanol (BOE), 4-tert-Butoxystyrene (BOS), Branched polyethyleneimine (BPEI), 3-Bromo-5-((trimethylsilyl)ethynyl)benzenesulfonyl fluoride (BTMSEBS), ε-Caprolactone (CAP), Carboxybetaine methacrylate (CBMA), 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite (CEDPCPP), N-Cyclohexylmaleimide (CHMI), 3-Chloro-2-hydroxypropyl methacrylate (CHPMA), Dodecyl acrylate (DA), N,N-Diallylacrylamide (DAA), Diallylmethylamine (DAMA), Diallyldimethylammonium chloride (DADMAC), 2,5-Diaminopyridine (DAP), 5,5′-Dibromo-4,4′-didodecyl-2,2′-bithiophene (DBDDBT), 5,5′-Dibromo-4,4′-ditetradecyl-2,2′-bithiophene (DBDTBT), 2,5-Dibromo-3-hexylthiophene (DBHTP), Dichloromethylvinylsilane (DCMVS), 2-(Diethylamino)ethanethiol hydrochloride (DEAET), 2-(Diethylamino)ethyl methacrylate (DEAEMA), Diethyl oxalpropionate (DEOP), DL-Lactide (DLL), N,N-dimethylamino-2-ethylmethacrylate) (DMA), N-[3-(N,N-dimethylamino)propyl]-methacrylamide (DMAPMA), [2-(Methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (DMAPS), N,N′-dimethylbutylamine (DMBA), N,N′-dimethylethanolamine (DMEA), N,N-dimethylamino-2-ethylacrylate or 2-(dimethylamino)ethyl acrylate (DMAEA), 1-(Dimethylamino)pyrrole (DMAP), 4,5-Dimethoxy-2-nitrobenzyl alcohol (DMONBA), 3,4-Dimethoxythiophene (DMOT), 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 2-deoxy-2-methacrylamido glucopyranose (DOMAAG), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP), 1,2-Diphytanoyl-sn-glycero-3-phosphoethanolamine (DPyPE), 3-Dodecylthiophene (3-DT), N-[2-(2-pyridyldithio)]ethyl methacrylamide (DTEMA), Ethyl acrylic acid (EAA), Ethyl 2-(bromomethyl)acrylate (EBMA), Ethyl 1-cyano-1-cyclopropanecarboxylate (ECCPC), 3,4-Ethylenedioxythiophene (EDOT), Ethylene glycol dimethacrylate (EGDMA), Ethylene glycol phenyl ether acrylate (EGPEA), Ethyl methacrylate (EMA), 3-(Fluorosulfonyl)-5-((trimethylsilyl)ethynyl)benzoic acid (3FTMSEBA), 3-Formyl-5-((trimethylsilyl)ethynyl)benzenesulfonyl fluoride (3FTMSEBS), 4-Formyl-2-((trimethylsilyl)ethynyl)benzenesulfonyl fluoride (4FTMSEBS), 5-Fluoro-2,3-thiophenedicarboxaldehyde (SFTPDCA), N-acetyl-D-galactose (GalNAc), N-acetyl-D-glucose (GlcNAc), Glycidyl methacrylate (GMA), Glycosylphosphatidylinositol (GPI), 5,7-Hexadecadiynoic acid (HDDA), 2-Hydroxyethyl methacrylate (HEMA), 1,1,1,3,3,3-Hexafluoroisopropyl acrylate (HFIPA), 1,1,4,7,10,10-Hexamethyltriethylenetetramine (HMTETA), 4-Hydroxybutyl acrylate (HOBA), 2-(4-Hydroxyphenylazo)benzoic acid (HPABA), 2,2,3,3,4,4,4-Heptafluorobutyl acrylate (HPFBA), N-(2-Hydroxypropyl)-Methacrylamide (HPMA), 2,2,3,4,4,4-Hexafluorobutyl acrylate (HXFBA), Isobornyl acrylate (IBA), 4-Iodobenzoyl chloride (IBC), Isobornyl methacrylate (IBMA), N-(Isobutoxymethyl)acrylamide (IBMAA), Isodecyl acrylate (IDA), Maleic anhydride (MA), [2-(Methacryloyloxy)ethyl] trimethylammonium chloride (MAETMA), Methacryloyl-L-Lysine (MAL), Methacryloxysuccinimide (MAS), Methacrylamidotrehalose (MAT), Methyl heptadecanoate (MHD), 1-Methyl-1H-indole-3-carbaldehyde (MICA), 2-N-Methylmaleimide (MMI), Methyl-5-norbornene-2,3-dicarboxylic anhydride (MNDCA), Methoxyethyl methacrylate (MOEMA), 2-(2-Methoxyethoxy)ethyl methacrylate (MOEOEMA), 3-Methyl-3-oxetanemethanol (MOM), 2-Methacryloyloxyethyl phosphorylcholine (MPC), Methyl 4-vinylbenzoate (MVB), 2-Naphthyl acrylate (NA), N-(Acryloxy)succinimide (NAS), o-Nitrobenzyl methacrylate (NBMA), N-Hydroxysuccinimide (NHS), N-(Methacryloxy)succinimide methacrylate (NHSMA), N-Isopropylacrylamide (NIPAM), 2-Naphthyl methacrylate (NMA), N-(Methacryloyloxy)succinimide (NMS), N-(n-Octadecyl)acrylamide (NODAA), 4-Nitro-N-propylbenzylamine hydrochloride (NPBAHC), Oligoethylene glycol methacrylate (OEGMA), Oligoethylenimine (OEI), 3-Phenylthiophene (3-PTP), Poly(N-methyl 4-vinylpyridine iodide) (P4VPQ), Poly(2-aminoethylmethacrylamide) (PAEMA), N—(N′—{N″—[N″′-(2-aminoethyl)-2-aminoethyl]-2-aminoethyl}-2-aminoethyl)-aspartamide (Asp(TEP)), 4-Pentenoic anhydride (PAN), Pentabromobenzyl acrylate (PBBA), Pentabromobenzyl methacrylate (PBBMA), Pentabromophenyl acrylate (PBPA), Pentabromophenyl methacrylate (PBPMA), Poly(ε-caprolactone) (PCL), trans-2-Phenylcyclopropyl isocyanate (PCPI), 1,5-Pentanediol (PD), 2-Phenyl-1,3-dioxan-5-ol (PDO), Pyridyl disulfide ethyl methacrylate (PDSEMA), Poly(ethylene glycol) (PEG), Poly(ethylene glycol) acrylate (PEGA), Poly(ethylene glycol) methyl ether methacrylate (PEGMEMA, Poly(ethylene glycol) ethyl ether methacrylate (PEGEEMA), Poly(ethylene glycol) methacrylate (PEGMA), Pentaethylenehexamine (PEHA), Poly(ethylenimine) (PEI), Pentaerythritol tetraacrylate (PETA), Pentafluorophenyl (PFP), Pentafluorophenyl acrylate (PFPA), Pentafluorophenyl methacrylate (PFPMA), Poly(glutamic acid) (PGA), Poly-(glycoamidoamine) (PGAA), Poly(glycidylbutylamine) (PGBA), Poly(glycidyl methacrylate) functionalized with ethanolamine (PGEA), Poly(glycidyl methacrylate) (PGMA), Poly(N-(2-Hydroxypropyl)methacrylamide) (PHPMA), Poly(lactic acid) (PLA), Poly(L-glutamate), (PLG), Poly(lactic-co-glycolic acid) (PLGA), Poly(L-lysine) (PLL), Poly(L-lactic acid) (PLLA), Poly(lauryl methacrylate) (PLMA), Poly(methacrylic acid) (PMAA), Poly-(2-deoxy-2-methacrylamido glucopyranose) (PMAG), Poly-(methyl methacrylate) (PMMA), Poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), Poly[N-(3-(methacryloylamino) propyl)-N,N-dimethyl-N-(3-sulfopropyl) ammonium hydroxide] (PMPD), Poly(n-butyl acrylate) (PnBA), Poly(n-butyl methacrylate) (PnBMA), Poly(N-isopropyl acrylamide) (PNIPAM), Poly(oligoethylene glycol methacrylate) (POEGMA), Poly(propylene glycol) (PPG), Poly(propylenimine) (PPI), 3,4-Propylenedioxythiophene (ProDOT), Poly(styrene) (PS), Poly(sodium 4-styrenesulfonate) (PSS), Poly(tributyl-(4-vinylbenzyl)phosphonium chloride) (PTBP), Poly(triethyl-(4-vinylbenzyl)phosphonium chloride) (PTEP), Poly((2-trimethylamino)ethyl metacrylate chloride) (PTMAEMA), Poly((vinylbenzyl) trimethylammonium) (PVBTMA), Poly(2-vinyl-4,4-dimethylazlactone) (PVDMA), Poly(N-ethyl-4-vinylpyridinium bromide) (PVP), Quaternized Poly-DMAEMA (QPDMAEMA), Sulfobetaine methacrylate (SBMA), 3-Sulfopropyl methacrylate potassium salt (SPMAP), Thiocholesterol (TC), Thiophene-2,5-diboronic acid bis(pinacol) ester (TDABP), Triethylene glycol dimethacrylate (TEGDMA), Trifluoroethylene (TFE), 2,2,2-Trifluoroethyl acrylate (TFEA), 2,2,2-Trifluoroethyl methacrylate (TFEMA), Tetrahydrofurfuryl acrylate (THFA), Triallylisocyanurate (TIC), Trimethylene Carbonate (TMC), 4,4′-Trimethylenedipiperidine (TMDP), Trimethylolpropane tris(3-mercaptopropionate) (TMPTMP), (Trimethylsilyl)methacrylate (TMSMA), Triphenylcarbenium pentachlorostannate (TPCPCS), 3-Vinylbenzaldehyde (3VBA), 4-Vinylpyridinium chloride (4VP), Vinyl acrylate (VA), Vinyl acetate (VAT), 4-Vinylbenzoic acid (VBA), (Vinylbenzyl)trimethylammonium chloride (VBTAC), 1-Vinylimidazole (VI), 1-Vinyl-2-pyrrolidone (VP), m-Xylylenediamine (XDA), Zinc stearate (ZS), and the like.
In some embodiments, the monomer units used to make Block 1 and/or Block 2 of RAFT copolymers as described herein are selected from the group consisting of 2-(dimethylamino) ethyl acrylate (DMAEEA), 2-(diethylamino) ethyl methacrylate (DEAEEA), 2-(diisopropylamino) ethyl methacrylate (DIEAMA), butyl methacrylate (BMA), ethyl acrylic acid (EAA), propyl acrylic acid (PAA), (hydroxyethyl)methacrylate, and methyl methacrylate (MMA).
In some embodiments, the RAFT copolymers provided herein can be described by the formula:
CTACap-[(B1M1)m-B1M2-B1M3-(B1M2)-m-B1M1-B1M3-(B1M3)-m-B1M1-B1M2]m-[(B2M1)n-B1M2-B1M3-(B2M2)-n-B1M1-B1M3-(B2M3)-n-B1M1-B1M2]n-CTACap
For example, a RAFT copolymer as described herein having a single monomer in Block 1 of 25 units and 3 different monomers in Block 2 having an average monomer unit ratio of 20:10:5 for a total n of 35, can be described by the general formula
CTACap-[B1M1]25-[(B2M1)20-(B2M2)10-(B2M3)5]-CTACap
It will be further appreciated that the polymers prepared using a RAFT polymerization are random polymers having a distribution of units and hence molecular weights. Therefore, the cartoon representation of Block 2 in the example above is a random copolymer comprising 35 monomer units of B2M1, B2M2, and B2M3 in the ratio described above.
In another illustrative embodiment, the polymer nanoparticle composition can be coated with one or more polymers to protect the compositions from immune responses or to enhance endosomal escape. In one embodiment, the one or more polymers comprise polyethylene glycol. In another embodiment, the one or more polymers comprise polyethylene glycol poly-L-lysine. In yet another embodiment, the one or more polymers comprise polyethylenimine. In an additional embodiment, the one or more polymers comprise polyethylene glycol poly-L-lysine and polyethylenimine.
It will be appreciated that tuning the parameters and properties of the RAFT copolymers described herein can be advantageous to their use in the compositions and methods as described herein. Accordingly, the methods for preparing RAFT copolymers either in singleton or in library format as described herein are capable of providing particular parameters and properties of the RAFT copolymers.
In some embodiments, a RAFT block polymer as described herein has one or more of an overall molecular weight (Mn) (i.e. the total of all blocks) in the range of about 1 kDa to about 1000 kDa, or about 2 kDa to about 500 kDa, or about 2 kDa to about 160 kDa, and overall degree of polymerization in the range of about 10 to about 3500, or about 20 to about 2500, or about 30 to about 900, a size in the range of about of about 10 nm to about 10000 nm, and a maximum corona-to-core ratio (CCR) of about 1 to about 4. In some embodiments, the overall molecular weight (Mn) in the range of about 30 kDa to about 120 kDa, about 40 kDa to about 110 kDa about 50 kDa to about 100 kDa, about 60 kDa to about 90 kDa, about 40 kDa to about 80 kDa, and about 40 kDa to about 60 kDa. In some embodiments, the overall degree of polymerization in the range of about 40 to about 850, about 60 to about 800, about 100 to about 700, about 200 to about 600, or about 300 to about 500. In some embodiments, the size is in the range of about of about 10 nm to about 10000 nm, or about 20 nm to about 5000 nm, or about 50 nm to about 3000 nm, or about 20 nm to about 1000 nm, or about 50 nm to about 1000 nm, or about 30 nm to about 500 nm, or about 200 nm to about 2000 nm, or about 100 nm to about 5000 nm, or about 100 nm to about 500 nm, or about 10 nm to about 50 nm, about 15 nm to about 45 nm, about 20 nm to about 40 nm, or about 25 nm to about 35 nm. In some embodiments, the maximum corona-to-core ratio (CCR) is less than 4, or less than 3, about 1 to about 3.8, about 1.2 to about 3.5, about 1.5 to about 3, about 1.5 to about 2.5, or about 1 to about 2.
In some embodiments, a first block can be prepared from one or more monomer units and have a molecular weight (Mn) in the range of about 1 kDa to about 500 kDa, or about 10 kDa to about 200 kDa, or about 10 kDa to about 160 kDa, or about 1 kDa to about 80 kDa, and a degree of polymerization in the range of about 10 to about 3500, or about 10 to about 2500, or about 20 to about 2000, or about 50 to about 1200, or about 50 to about 1000. In some embodiments, a first block molecular weight (Mn) can be in the range of about 1 kDa to about 500 kDa, or about 2 kDa to about 400 kDa, or about 5 kDa to about 200 kDa, or about 10 kDa to about 160 kDa, or about 15 kDa to about 100 kDa, or about 25 kDa to about 60 kDa, or about 30 kDa to about 55 kDa, about 30 kDa to about 50 kDa, or about 30 kDa to about 40 kDa, and the like. In some embodiments, the first block degree of polymerization is in the range of about 30 to about 350, about 50 to about 300, about 70 to about 250, about 80 to about 240, about 100 to about 200, and the like.
In some embodiments, the second block can be prepared from one or more monomer units, and can have a molecular weight (Mn) in the range of about 1 kDa to about 500 kDa, or about 10 kDa to about 200 kDa, or about 10 kDa to about 160 kDa, or about 1 kDa to about 80 kDa, and a degree of polymerization in the range of about 10 to about 3500, or about 10 to about 2500, or about 20 to about 2000, or about 50 to about 1200, or about 50 to about 1000. In some embodiments, the second block molecular weight (Mn) is in the range of about 10 kDa to about 70 kDa, about 15 kDa to about 65 kDa, about 20 kDa to about 60 kDa, about 25 kDa to about 55 kDa, about 30 kDa to about 50 kDa, about 35 kDa to about 45 kDa, about 5 kDa to about 15 kDa, and the like. In some embodiments, the second block degree of polymerization is in the range of about 3 to about 2500; or about 20 to about 2000, or about 30 to about 1500, or about 40 to about 1200, or about 10 to about 500, or about 12 to about 450, or about 20 to about 400, or about 25 to about 350, or about 50 to about 300, or about 100 to about 250, or about 150 to about 200, or about 5 to about 50, or about 5 to about 20, and the like.
In some embodiments, a third, fourth, or subsequent block can be prepared from one or more monomer units, and each can have a molecular weight (Mn) in the range of about 1 kDa to about 500 kDa, or about 10 kDa to about 200 kDa, or about 10 kDa to about 160 kDa, or about 1 kDa to about 80 kDa, and a degree of polymerization in the range of about 10 to about 3500, or about 10 to about 2500, or about 20 to about 2000, or about 50 to about 1200, or about 50 to about 1000. In some embodiments, the third, fourth, or subsequent block molecular weight (Mn) is in the range of about 10 kDa to about 70 kDa, about 15 kDa to about 65 kDa, about 20 kDa to about 60 kDa, about 25 kDa to about 55 kDa, about 30 kDa to about 50 kDa, about 35 kDa to about 45 kDa, about 5 kDa to about 15 kDa, and the like. In some embodiments, the third, fourth, or subsequent block degree of polymerization is in the range of about 3 to about 2500; or about 20 to about 2000, or about 30 to about 1500, or about 40 to about 1200, or about 10 to about 500, or about 12 to about 450, or about 20 to about 400, or about 25 to about 350, or about 50 to about 300, or about 100 to about 250, or about 150 to about 200, or about 5 to about 50, or about 5 to about 20, and the like.
In some embodiments, a single chain transfer agent can be used in the RAFT polymerization process in connection with the present disclosure. In some embodiments, for a block polymer having more than one block, one or more single chain transfer agents can be used in the RAFT polymerization process in connection with the present disclosure. In some embodiments, for a block polymer having two blocks, a first chain transfer agent and a second chain transfer agent (which can be the same or different) can be used at each step of the RAFT polymerization process in connection with the present disclosure. In some embodiments, for a block polymer having three blocks, a first chain transfer agent, a second chain transfer agent, and a third chain transfer agent (which can be the same or different) can be used at each step of the RAFT polymerization process in connection with the present disclosure.
It will be appreciated that a variety of solvents can be used in the RAFT polymerization method steps and purification steps described herein. Suitable solvents include, but are not limited to, 2-Chloroethanol, Acetic Acid (Glacial), Acetone, Acetonitrile, Acetophenone, Aniline, Benzaldehyde, Benzyl Acetate, Carbon disulfide, Cyclohexane, Cyclohexanol, Di(ethylene glycol), Di(propylene glycol), Diacetone alcohol, Diethyl ether, Dimethylsulfoxide, Ethanol, Ethyl acetate, Ethylene glycol, Formaldehyde (37% solution), Formamide, Formic acid, Formic acid (96%), Hexanelsobutanol, Isopropanol, Isopropyl acetate, Isopropyl ether, m-Cresol, Methanol, Methyl acetate, Methyl ethyl ketone, Mineral Oil, N,N-Dimethylformamide, n-Butanol, n-Octane, n-Propanol, Propylene glycol, Pyridine, t-Butanol, Tetrahydrofuran, Trifluoroacetic acid, water, and the like, and combinations thereof.
In some embodiments, the one or more nanoparticle forming polymers are RAFT block copolymers comprising
Illustrative payloads for the polymer nanoparticle described herein can include any one or a combination of compositions selected from the group comprising: nucleic acids (e.g., DNA or RNA), pDNA, oligodeoxyribonucleic acids (ODNs), dsDNA, ssDNA, antisense oligonucleotides, antisense RNA, siRNA, messenger RNA, guide RNA (e.g., small guide RNA), ribonucleoproteins, donor DNA strands used in the CRISPR/Cas9 system, and enzymes, such as CRISPR-associated enzymes, e.g., Cas9, enzymes used in other gene editing systems, such as ZFNs, custom designed homing endonucleases, TALENS systems, other gene editing endonucleases, and reverse transcriptase.
In another aspect, the present disclosure rapidly identifies top candidates using a machine learning model. In the illustrative embodiment, a graph neural network (GNN) is used for this process. Polymers can be characterized at three scales: monomer, block, and full polymer. Monomers combine to form blocks, and blocks combine to form full polymers. Polymer properties are dependent on characteristics of the polymer at all three scales. The relationships between monomers, blocks, and polymers can be captured with a directed graph. Information can then be shared between nodes in the graph to create a numerical representation of the full polymer at all three scales: monomer, block, and polymer. These numerical representations can then be used in a neural network to prediction properties of the polymer. The use of a GNN for polymer property prediction in the illustrative embodiment provides two primary benefits: first, the graph can model polymer characteristics at all three scales which is important for accurate prediction; second, the graph provides a flexible modeling structure that can accommodate several polymer structures.
The machine learning model is first trained on a combination of public data and preliminary testing data, supplemented with the large data sets described above. The illustrative embodiment involves a three-loop deep learning cycle to accelerate high-throughput characterization and screening for PNPs. The three deep learning loops characterize the PNP physical properties, in vitro bioactivity, and in vivo bioactivity, respectively. Each loop utilizes a GNN deep learning model (see
The presently disclosed architecture offers at least three distinct advantages. First, the deep learning model is not dependent on polymer fingerprinting. Rather, the deep learning model will learn an appropriate numerical embedding from the SMILES strings. Second, the graph allows the model the flexibility to represent various families of PNPs with ease. Third, using SMILES strings as inputs allows the limited training dataset to be augmented with enumerated SMILES strings, increasing the amount of training data available and improving the model performance. Testing of this GNN architecture has shown impressive ability to predict zeta potential (see
In some embodiments, data augmentation may be performed to artificially increase the size and variety of the data used to train the machine learning model (and, consequently, increase model performance). Deep learning models require relatively large datasets for training and can over-fit to small datasets. As discussed above, the GNN takes the SMILES strings defining the monomers as an input. A monomer (a building block of a polymer) has a single canonical SMILES string, but it also has multiple alternative SMILES string representations. SMILES enumeration can be performed to generate these alternative forms from the canonical SMILES string and, thus, increase the size of the training data set many times over. The neural network model is then able to leverage this increase in data size and variety of representations to improve performance.
In other embodiments, a modified Transformer model (rather than a GNN) may be used to predict polymer properties (and, thus, rapidly identify top candidates for non-viral carriers for delivering base editing proteins, among other applications). The modified Transformer model exploits relative positional information of inputs to create numerical embeddings for monomer string inputs. These numerical embeddings can then be used in deep learning and statistical models for polymer property prediction. Additionally, the Transformer model is more computationally efficient compared to many other deep learning architectures that can process sequential data. The original Transformer architecture consists of an encoding and decoding architecture. The encoder takes an input sequence of data and outputs a high dimensional embedding, while the decoder takes the high dimensional embedding as an input and tries to predict the original or similar sequence to the one input into the encoder. The present disclosure does not need to predict a sequential output, so it only uses the encoding portion of the Transformer to predict polymer properties, both physical and in-vitro/in-vivo.
In yet another aspect, an illustrative embodiment of the present disclosure allows for the selection the top candidates for PNP-mediated delivery of the SOD1-targeting CBE in a mouse model of ALS. Functional gene editing tests in a microglial cell line stably expressing EGFP or SOD1 can then be performed using these top candidates. Moreover, the efficacy and safety PNP-mediated CBE delivery can be assessed in the G93A-SOD1 mouse model of ALS. Prior success of CBE base editors for slowing ALS progression in mice shows a likelihood that they can also lead to clinical translation of a novel ALS gene editing therapy.
While certain illustrative embodiments have been described in detail in the drawings and the foregoing description, such an illustration and description is to be considered as exemplary and not restrictive in character, it being understood that only illustrative embodiments have been shown and described and that all changes and modifications that come within the spirit of the disclosure are desired to be protected. There exist a plurality of advantages of the present disclosure arising from the various features of the apparatus, systems, and methods described herein. It will be noted that alternative embodiments of the apparatus, systems, and methods of the present disclosure may not include all of the features described, yet still benefit from at least some of the advantages of such features. Those of ordinary skill in the art may readily devise their own implementations of the apparatus, systems, and methods that incorporate one or more of the features of the present disclosure.
Barcode Design
The nucleic acid constructs used in this example comprised a unique portion comprising 8-10 nucleotides in the center of the polynucleotide, the unique portion further constrained by the requirement of a hamming distance of at least 3 bases from any other barcodes to be pooled. Directly on the 3′ end of the barcode, 7-10 random bases are included for bioinformatic removal of PCR duplicates. This central sequence is flanked by universal primer annealing sites containing overhangs for the addition of index adapters during sequencing library preparation.
Polymer Nanoparticle Synthesis
A diblock copolymer was synthesized as described in PCTapp349529(21477779.1) using reversible addition-fragmentation chain transfer (RAFT) polymerization with reagents and amounts listed in Table 2. Block 1 reagents were combined in a round bottom flask, purged with argon, and heated to 60° C. for 6 hours using a heating mantle. The reaction product was purified using four 80:20 pentane:ether precipitation washes and centrifugation cycles and dried in vacuo. The Block 1 product was used as the macroRAFT agent for Block 2, and the calculated reagent volumes (as calculated based on theoretical molecular weight information for Block 1) were combined in a round bottom for the Block 2 reaction. The reaction mixture was argon purged before being heated at 60° C. for 24 hours. The reaction product was purified using the same purification process and dried in vacuo. The resulting polymer was dialyzed in deionized water for 4 days with multiple water changes each day. Finally, the dialyzed material was lyophilized for 4 days and stored at room temperature for experimental use.
RAFT copolymers were synthesized according to the methods above and the reagents listed in Table 2. The polymer was dispersed in phosphate buffered saline at a concentration of ˜5 mg/ml. For electrostatic loading (
RAFT copolymers made using CTAs that contain at least one carboxyl terminal group were further functionalized with avidin (
To test the range of PNP to barcode ratios that can be used in the reduction to practice of nucleic acid constructs labeled PNPs, the method above was used to attach the nucleic acid constructs to PNPs using the avidin-biotin linkage (
The avidin-biotin conjugation method was used to attach 96 unique barcodes to 96 aliquots of the polymer described in Table 2, yielding 96 aliquots of the same polymer in which the population of nanoparticles in each aliquot has a unique barcode attached. These 96 aliquots were pooled by combining the aliquots in volumetrically equivalent amounts into a single vial, yielding a dispersion of 96 distinct populations of barcoded PNPs, in which all populations comprised a polymer micelle formed from the polymer described in Table 2 and a unique barcode from the population of 96 unique barcodes.
The pooled sample of avidin-biotin conjugated nucleic acid construct-PNPs were spiked into HEK-293T cells. The cells were seeded in 96 well plates at 20,000 cells per well, in 100 μL of media and left to adhere overnight. Twenty-four hours after seeding, the pooled sample of PNPs with 96 unique barcodes were added at a dose of ˜0.024 mg/mL PNP in each well and placed in an incubator at 37° C. overnight. The next day, barcodes extracted from the samples, using the QlAamp 96 DNA extraction kit and a Qiacube HT instrument according to the manufacturer's protocol. The conjugated barcodes were amplified via PCR, using primers designed to bind to the universal primer binding sequences on the barcodes. The amplicons were detected via gel electrophoresis on agarose gel. The presence of a double band (
The pooled sample of PNPs with 96 unique barcodes conjugated via avidin-biotin linkage, was administered to mice (using the in vivo screening protocol described below). Twenty-four hours after dosing, the mice were sacrificed and the tissues were analyzed for the presence of the barcoded PNPs. PCR was used to amplify the barcodes from the tissue samples and agilent fragment analysis was used to detect the presence of nucleic acid constructs-PNPs, with a dark band matching the positive control as the indicator of the presence of nucleic acid constructs-PNPs (
Preparation of RAFT Copolymers for Polymer Nanoparticle Libraries
Briefly, Block 1 reagents (monomer(s), chain transfer agent, initiator, and solvent) were combined in wells of a polypropylene 96-well u-shaped bottom microplate (Greiner Bio-One), in polypropylene 96 well cluster tubes (Corning), in polypropylene Eppendorf microcentrifuge tubes (Sigma-Aldrich), or in polypropylene 50 mL or 15 mL conical tubes (VWR) and placed in a VWR 1400E Sheldon vacuum oven. A 20 mL glass vial was filled with approximately 10-15 mL of solvent (e.g., dimethylformamide), and the vial was placed in the oven to provide a source for atmosphere saturation. The oven was purged with argon at ˜3 L/min for approximately 45 minutes and heated to between 60° C. and 75° C. for 6-24 hours. Upon completion of the reaction, acetone was added to the wells or tubes to prevent polymer solidification and the wells or tubes were sealed and left at room temperature overnight. The next day, the reaction product solutions were transferred to 1.5 mL Eppendorf tubes (if necessary) and purified via at least three precipitation washes using an appropriate purification solvent solution (e.g., 80:20 pentane:ether, isopropyl alcohol, methanol, etc.) and centrifugation cycles and dried in vacuo. The Block 1 product was used as the macroRAFT agent for Block 2, and the calculated reagent volumes (as calculated based on theoretical or actual molecular weight information for Block 1) were combined in a polypropylene 96-well u-shaped bottom microplate (Greiner Bio-One), in polypropylene 96 well cluster tubes (Corning), in polypropylene Eppendorf microcentrifuge tubes (Sigma-Aldrich), or in polypropylene 50 mL or 15 mL conical tubes (VWR) for the Block 2 reaction. The reaction mixtures were placed in a VWR 1400E Sheldon vacuum oven, which was argon purged at ˜3 L/min for approximately 45 minutes before being heated to between 60° C. and 75° C. for 6-24 hours. The reaction products were purified using the same purification process as used for Block 1 library materials and dried in vacuo. The resulting polymers were resuspended in either acetone or chloroform and aliquoted as needed for experimental use (these transfer solvents evaporated prior to material use), stored in a dry state at room temperature, or dissolved in deionized water, frozen, and lyophilized prior to experimental use. Size was measured using a Wyatt Technology DynaPro Plate Reader III. Molecular weights for Block 1 materials were measured using a DynaPro Plate Reader III. Nanoparticle sizes above the DynaPro Plate Reader III molar mass capability threshold prevented measurement of Block 2 molecular weights for these polymer libraries. All molecular weights for high-throughput polymer libraries are reported as weight average molecular weight (Mw).
A summary of the reagents, amounts, and reaction conditions used to synthesize Block 1 and Block 2 of a pilot PNP library of 96 PNPs are shown in Tables 3 and 4, respectively, below. PNPs 22, 61, and 89-96 were used as 10 unique PNPs for HEK cell studies. PNPs 1-88 were used as unique PNPs for flow cytometry studies. Table 3 Abbreviations: ACVA, 4,4′-Azobis(4-cyanovaleric acid); AIBN, Azobisisobutyronitrile; BMA, butyl methacrylate; CTP, 4-Cyano-4-(thiobenzoylthio)pentanoic acid; DMAEMA, dimethylaminoethyl methacrylate; DMF, N,N-Dimethylformamide; ECT, 4-Cyano-4-[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid; MMA, methyl methacrylate. Table 4 Abbreviations: ACVA, 4,4′-Azobis(4-cyanovaleric acid); AIBN, Azobisisobutyronitrile; BMA, butyl methacrylate; CTP, 4-Cyano-4-(thiobenzoylthio)pentanoic acid; DMAEMA, dimethylaminoethyl methacrylate; DMF, N,N-Dimethylformamide; ECT, 4-Cyano-4-[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid; HEMA, 2-Hydroxyethyl methacrylate; MMA, methyl methacrylate. Table 5 Abbreviations: PDI, polydispersity index.
Static Light Scattering (SLS) and Dynamic Light Scattering (DLS) measurements to determine Block 1 molar mass and PNP size (e.g., diameter) were determined using a DynaPro Plate Reader III by Wyatt Technology. Data acquisition and handling were made with DYNAMICS software. SLS and DLS data were obtained under the following conditions:
RAFT copolymers made using CTAs that contain at least one carboxyl terminal group were further functionalized with amine terminal DNA barcodes. A RAFT copolymer was transferred into a MES buffer at ˜12 mg/mL. The sample was sonicated for 30 minutes. EDC reagent and Sulfo-NHS reagent was added to the polymer at a molar ratio of 10:1 and 25:1 respectively, reagent to PNP. The sample was incubated for at least 10 minutes at room temperature to allow the reaction to occur. The reaction volume was filtered through a membrane with a molecular weight cut off of 30 kDa via centrifuge at ˜3000× g for ˜15 minutes. The filtrate was discarded, and sterile PBS was added to the retentate to reconstitute to 10 mg/mL polymer. A nucleic acid constructs with a primary amine group attached to the 5′ end was added to polymer and the sample was incubated for at least 15 minutes. The sample was transferred to an amicon ultra-4 centrifuge tube (MWCO 30 kDa, Max 3.5 mL/Tube) and centrifuged at 4,000× g for 15 minutes to remove any unbound nucleic acid constructs. The filtrate (containing unbound nucleic acid constructs) was discarded and sterile PBS was added to the retentate to final concentration of 8 mg/mL polymer. The conjugated barcodes were amplified via PCR, using primers designed to bind to the primer binding segments on the nucleic acid constructs. The amplicons were detected via gel electrophoresis on agarose gel. The presence of a double band (
The direct amidification method was used to attach 10 unique barcodes to 10 unique PNPs. The 10 unique PNPs were prepared according to the reagents shown in EXAMPLE 5.
Subsequently, the direct amidification method was used to attach 10 unique DNA barcodes to each PNP, giving each a unique label. The nucleic acid construct-PNPs were loaded with a pDNA encoding for the expression of tdTomato red fluorescent protein, and then used to treat HEK-293T cells at ˜0.024 mg/mL PNP, 24 hours after seeding in a 96 well plate at 20,000 cells per well. They were left to incubate for another 48 hours, at which time, expression of the payload was observed via fluorescence microscopy using a Texas Red filter set (
The direct amidification method was then used to attach 88 unique barcodes to 88 unique PNPs. The 88 unique PNPs were prepared according to the reagents shown in EXAMPLE 5. The amidification method was then used to attach 88 unique DAN barcodes to each PNP giving each a unique label. The nucleic acid construct-PNPs were loaded with a pDNA encoding for the expression of tdTomato red fluorescent protein, and then used to treat HEK-293T cells at ˜0.024 mg/mL PNP, 24 hours after seeding in a 96 well plate at 20,000 cells per well. They were left to incubate for another 48 hours, at which time, expression of the payload was measured via flow cytometry using a Cytoflex (
Methods for Screening Nucleic Acid Construct-PNPs In Vitro and In Vivo
The pooled sample of polymer nanoparticles produced from the recipe in Table 2, with 96 unique barcodes attached via avidin-biotin linkange, was used for measuring cell uptake and cytotoxicity in vitro in HEK293T cells, and for measuring biodistribution in vivo administration in mice. nucleic acid construct-PNPs were formulated in a sterile saline solution and stored at 4° C. for up to 1 month prior to in vivo dosing. Cell uptake efficiency and cytotoxicity are assessed in vitro using HEK293T cells with 0.024 mg/mL PNP at 250 ng or 150 ng/well pDNA treatment concentrations. Cell uptake was demonstrated by fluorescence microscopy. Animals are assigned to dose groups using a stratified randomization program designed to maintain similar group mean body weights by sex. Animals are administered either a control or test article via a single bolus intravenous tail-vein injections. Tested doses ranged from 0-150 mg/kg, with adverse clinical events being observed in 35% of animals at 150 mg/kg. Blood and tissue are collected from all animals and snap frozen in liquid nitrogen.
Extraction of Nucleic Acid Construct-PNPs from In Vitro Biological Samples
10-20 mg of tissues are placed in a Tris-EDTA lysis buffer and homogenized using the TissueLyser bead-beating system and a 5 mm stainless steel bead. Homogenization is carried out at 25 Hz in 5-7 minute intervals until solution is homogenous in appearance. Proteinase K is then added to the lysate for protein digestion and incubated in a Thermomixer at 55° C. for 2-4 hours. DNA is extracted from the tissue lysate using the QlAamp 96 DNA extraction kit and a Qiacube HT instrument according to the manufacturer's protocol. Concentration and purity of isolated samples is determined using a NanoDrop.
PCR Amplification of Polynucleotide Barcodes in Nucleic Acid Constructs
Polymerase chain reaction is used to produce amplicons from extracted nucleic acid constructs. PCR is performed using a single set of universal primers that anneal to the universal amplification sites on the barcode, thereby amplifying all unique barcodes within a sample in a single reaction. Positive amplification of barcode(s) within a sample is determined using electrophoresis (agarose gel or bioanalyzer) indicated by the presence of a band at ˜120 bp.
Library Preparation and Sequencing of Nucleic Acid Constructs
Sequencing libraries are prepared from the amplicons generated during first stage PCR amplification. Our universal primers also contain overhang sequences that enable attachment of Index Adapters for sequencing. Illumina Unique Dual Indexes are annealed to the overhangs on the amplicon by PCR. Individual indexed libraries are then pooled in equal amounts and purified using a NucleoSpin Gel and PCR Clean-up kit according the manufacturer's protocols. The molar concentration of the final sequencing library is determined using a Qubit dsDNA High Sensitivity Assay kit and Qubit Fluorometer. The library is spiked with 2% PhiX, diluted to 1.8 pM and loaded onto a High Output 300 cycle NextSeq sequencing cardrige. Paired end sequencing is performed using a NextSeq550 instrument.
Sequence Analysis and Bioinformatics
Merged reads from each Sample ID are demultiplexed into PE FASTQ files, and merged into a single file. The merged reads are processed to identify those containing both the 5′ and 3′ flanking adapters. Trimmed reads are then downselected for sequences containing the correct barcode length. Barcode counts are generated from these downselected sequences and tagged according to whether they are spiked or random. Barcode counts are then normalized to the number of FASTQ reads in the sample.
By way of example, in one illustrative embodiment, the presently disclosed rapid DBTL technologies may be used to develop a gene therapy for forms of amyotrophic lateral sclerosis (ALS) caused by toxic, gain-of-function mutations in superoxide dismutase 1 (SOD1). This gene therapy may involve delivering a CRISPR base-editing protein via a non-viral gene delivery vehicle to inactivate the production of mutant SOD1 protein in microglia, a cell type that modulates the progression of the disease but remains refractory to efficient viral transduction. This will enable safe and efficient therapeutic “hit-and-run” editing for ALS.
An exemplary disease that can be treated with the methods described herein is ALS. ALS is a rapidly progressive, paralytic, and invariably fatal disorder characterized by the selective loss of motor neurons in the spinal cord and brain. Though most cases of ALS are sporadic, dominantly inherited mutations in SOD1 (a ubiquitously expressed metalloenzyme that normally converts superoxide anions into oxygen and hydrogen peroxide) account for up to 20% of all inherited or familial forms of ALS. Base editors are a recently emerged gene-editing modality capable of introducing targeted single-base substitutions in DNA without the requirement for a double-strand break (DSB). Base editors consist of fusions of a catalytically impaired Cas9 nuclease variant, known as a Cas9 nickase, with a nucleobase deaminase enzyme. This example will rely on the ability of base editors, specifically cytidine base editors (CBEs), to catalyze C>T base transitions at CGA, CAG or CAA triplets in a target gene sequence, which creates an in-frame stop codon that triggers the degradation of a target mRNA by nonsense-mediated decay—a surveillance mechanism used by cells to prevent the formation of truncated proteins. Using this method, SOD1 will be inactivated in a manner that does not require a DSB and does not rely on the stochastic and mutagenic NHEJ repair pathway, thus overcoming two of the major limitations facing the clinical implementation of CRISPR-Cas9 for ALS. Thus, while first generation CRISPR is considered the “cut and paste” of gene editing, base editors are considered to be an “eraser and pencil” function, allowing for precise single base edits to a genome, opening new mechanisms for revolutionary ALS treatments. However, innovations in gene delivery have significantly lagged innovations in technologies for gene editing itself. Thus, efficient delivery of base editing systems to the specific cell types involved in driving the progression of ALS represents a key limitation impeding its safe and efficient implementation for treatment of the disorder. Non-viral delivery vehicles will be used to address many of these limitations.
In this illustrative example, the rapid DBTL technologies can iterate through hundreds of diverse polymer nanoparticle candidates, using automated high-throughput synthesis of diverse polymer nanoparticle libraries, parallel in vitro and in vivo screens of barcoded libraries, and a machine learning algorithm to analyze the large data sets and predict new libraries for rapid iteration.
In one aspect, a library of 100s of polymer nanoparticles (PNPs) encapsulating CBE mRNA can be screened in a high throughput in vitro and in vivo platform. In the illustrative embodiment, over 500 PNPs are synthesized and uniquely labeled and tracked via DNA barcoding. A highly versatile PNP platform based on reversible addition-fragmentation chain transfer (RAFT) polymerization will be used due to its flexibility, reproducibility, and scalability. See K. Sims et al., “Rigor and reproducibility in polymer nanoparticle synthesis and characterization,” Rsc Advances 2020, 10 (5), 2513-2518 (incorporated herein by reference). As shown in
After library synthesis, as described above, these PNPs can then be rapidly tested in vitro in a microglial cell line for toxicity, inflammation, and mRNA delivery efficiency via GFP expression. In parallel, the biodistribution and toxicity of the entire library can be assessed using loaded nanoparticles delivered via an intrathecal injection to the cerebrospinal fluid (CSF) of the G93A-SOD1 mouse model of ALS using an mRNA encoding a bioluminescent luciferase that can be tracked via in vitro imaging system (IVIS). This screen should result in three large data sets including particle physical characteristics, in vitro bioactivity, and in vivo biodistribution and toxicity, which, taken together, will provide the basis for an informed design of a novel non-viral delivery vehicle library which will be synthesized in a second iteration. This novel library can then be tested for functional gene editing tests in a microglial cell line modified to express a mutant SOD1 protein. The PNPs can be loaded with mRNA encoding CBE designed to inactivate GFP and SOD1, detected by fluorescence measurement and sequencing.
This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 63/172,069 filed on Apr. 7, 2021, the entire disclosure of which is incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3562806 | Grant et al. | Feb 1971 | A |
| 3678098 | Lewis et al. | Jul 1972 | A |
| 3691123 | Clarke et al. | Sep 1972 | A |
| 3706564 | Hollister et al. | Dec 1972 | A |
| 3706565 | Ericson | Dec 1972 | A |
| 3739042 | Chu et al. | Jun 1973 | A |
| 3744969 | Alps et al. | Jul 1973 | A |
| 3829564 | Merry et al. | Aug 1974 | A |
| 3847857 | Haag et al. | Nov 1974 | A |
| 4036766 | Yamamoto et al. | Jul 1977 | A |
| 4056559 | Lewis et al. | Nov 1977 | A |
| 4219616 | Pope et al. | Aug 1980 | A |
| 4237253 | Jacquet et al. | Dec 1980 | A |
| 4377481 | Jakabhazy | Mar 1983 | A |
| 4434268 | Doroszkowsky et al. | Feb 1984 | A |
| 4544621 | Roth | Oct 1985 | A |
| 4557997 | Iwasaki et al. | Dec 1985 | A |
| 4559293 | Moriya et al. | Dec 1985 | A |
| 4592816 | Emmons et al. | Jun 1986 | A |
| 4595722 | Such | Jun 1986 | A |
| 4656027 | Sjoovist | Apr 1987 | A |
| 4735887 | Foss et al. | Apr 1988 | A |
| 4755563 | West | Jul 1988 | A |
| 4775721 | Horikawa et al. | Oct 1988 | A |
| 4834799 | Song | May 1989 | A |
| 4855207 | Tsubuko et al. | Aug 1989 | A |
| 4925764 | Madeleine et al. | May 1990 | A |
| 4985160 | Henry et al. | Jan 1991 | A |
| 5085698 | Ma et al. | Feb 1992 | A |
| 5124381 | Ward | Jun 1992 | A |
| 5141556 | Matrick | Aug 1992 | A |
| 5180425 | Matrick et al. | Jan 1993 | A |
| 5205861 | Matrick | Apr 1993 | A |
| 5271765 | Ma | Dec 1993 | A |
| 5310595 | Ali et al. | May 1994 | A |
| 5310778 | Shor et al. | May 1994 | A |
| 5418277 | Ma et al. | May 1995 | A |
| 5428383 | Shields et al. | Jun 1995 | A |
| 5432035 | Katagiri et al. | Jul 1995 | A |
| 5512418 | Ma | Apr 1996 | A |
| 5518534 | Pearlstine et al. | May 1996 | A |
| 5519081 | Ashton et al. | May 1996 | A |
| 5519085 | Ma et al. | May 1996 | A |
| 5525450 | Spiewak et al. | Jun 1996 | A |
| 5620883 | Shao et al. | Apr 1997 | A |
| 5698016 | Adams et al. | Dec 1997 | A |
| 5709714 | Natoli et al. | Jan 1998 | A |
| 5750594 | Page et al. | May 1998 | A |
| 5969046 | Schindler et al. | Oct 1999 | A |
| 5985573 | Hennink et al. | Nov 1999 | A |
| 6004582 | Faour et al. | Dec 1999 | A |
| 6004712 | Barbetta et al. | Dec 1999 | A |
| 6022533 | Goto et al. | Feb 2000 | A |
| 6022908 | Ma et al. | Feb 2000 | A |
| 6040358 | Page et al. | Mar 2000 | A |
| 6077635 | Okado et al. | Jun 2000 | A |
| 6132917 | Hoffend et al. | Oct 2000 | A |
| 6139856 | Kaminska et al. | Oct 2000 | A |
| 6197290 | Goto et al. | Mar 2001 | B1 |
| 6207631 | Kasturi et al. | Mar 2001 | B1 |
| 6221402 | Itoh et al. | Apr 2001 | B1 |
| 6245421 | Aurenty et al. | Jun 2001 | B1 |
| 6247808 | Ma et al. | Jun 2001 | B1 |
| 6251554 | Hoffend et al. | Jun 2001 | B1 |
| 6276273 | Aurenty et al. | Aug 2001 | B1 |
| 6309666 | Hatano et al. | Oct 2001 | B1 |
| 6315854 | Anhauser et al. | Nov 2001 | B1 |
| 6372708 | Kasturi et al. | Apr 2002 | B1 |
| 6413306 | Kraiter et al. | Jul 2002 | B1 |
| 6471349 | Aurenty et al. | Oct 2002 | B1 |
| 6532871 | Aurenty et al. | Mar 2003 | B1 |
| 6624210 | Petereit et al. | Sep 2003 | B1 |
| 6692769 | Ishibashi et al. | Feb 2004 | B1 |
| 6720387 | Stark et al. | Apr 2004 | B1 |
| 6794367 | Tanida et al. | Sep 2004 | B1 |
| 6827795 | Kasturi et al. | Dec 2004 | B1 |
| 6903064 | Kasturi et al. | Jun 2005 | B1 |
| 7256020 | Lyamichev et al. | Aug 2007 | B2 |
| 7737108 | Hoffman et al. | Jun 2010 | B1 |
| 8758860 | Pyles et al. | Jun 2014 | B1 |
| 9085618 | Ramasubramanyan et al. | Jul 2015 | B2 |
| 9447220 | Cho et al. | Sep 2016 | B2 |
| 9714940 | Lowery, Jr. et al. | Jul 2017 | B2 |
| 9970040 | Elbaz et al. | May 2018 | B2 |
| 10201503 | Li et al. | Feb 2019 | B1 |
| 10695443 | Lötvall et al. | Jun 2020 | B2 |
| 20020028410 | Choi | Mar 2002 | A1 |
| 20020187311 | Golub et al. | Dec 2002 | A1 |
| 20030049311 | McAllister et al. | Mar 2003 | A1 |
| 20030064036 | Petereit et al. | Apr 2003 | A1 |
| 20030071883 | Suzuki et al. | Apr 2003 | A1 |
| 20030106160 | Sun et al. | Jun 2003 | A1 |
| 20030124074 | Mougin et al. | Jul 2003 | A1 |
| 20030130160 | Eason et al. | Jul 2003 | A1 |
| 20030152856 | Mizoe et al. | Aug 2003 | A1 |
| 20030199419 | Rodrigues et al. | Oct 2003 | A1 |
| 20040091538 | Pollock-Dove et al. | May 2004 | A1 |
| 20040096490 | Bracht et al. | May 2004 | A1 |
| 20040104501 | Petereit et al. | Jun 2004 | A1 |
| 20040109869 | Glenn et al. | Jun 2004 | A1 |
| 20040198838 | Alles et al. | Oct 2004 | A1 |
| 20040208925 | Oner et al. | Oct 2004 | A1 |
| 20040219211 | Criere et al. | Nov 2004 | A1 |
| 20040249035 | Petereit et al. | Dec 2004 | A1 |
| 20050020779 | Mougin et al. | Jan 2005 | A1 |
| 20050026803 | Sivik et al. | Feb 2005 | A1 |
| 20050048112 | Breitenbach et al. | Mar 2005 | A1 |
| 20050053566 | Nguyen-Kim et al. | Mar 2005 | A1 |
| 20050070486 | Wieland-Berghausen et al. | Mar 2005 | A1 |
| 20050084529 | Rosenberg et al. | Apr 2005 | A1 |
| 20050090599 | Spinelli | Apr 2005 | A1 |
| 20050208133 | Tsutsumi et al. | Sep 2005 | A1 |
| 20050281871 | Petereit et al. | Dec 2005 | A1 |
| 20060051412 | Petereit et al. | Mar 2006 | A1 |
| 20060089425 | Chopra et al. | Apr 2006 | A1 |
| 20060110433 | Terahara et al. | May 2006 | A1 |
| 20060257484 | Hwang et al. | Nov 2006 | A1 |
| 20060280798 | Ensoli | Dec 2006 | A1 |
| 20070027213 | Oberegger et al. | Feb 2007 | A1 |
| 20070072996 | Kedar et al. | Mar 2007 | A1 |
| 20070088118 | Dungworth et al. | Apr 2007 | A1 |
| 20070141013 | Nguyen-Kim et al. | Jun 2007 | A1 |
| 20070178059 | Moser et al. | Aug 2007 | A1 |
| 20070203245 | Koltun et al. | Aug 2007 | A1 |
| 20070231397 | Petereit et al. | Oct 2007 | A1 |
| 20070259028 | Ito | Nov 2007 | A1 |
| 20070275060 | Befumo et al. | Nov 2007 | A1 |
| 20070275071 | Ensoli et al. | Nov 2007 | A1 |
| 20080050432 | Jun et al. | Feb 2008 | A1 |
| 20080050450 | Arnold et al. | Feb 2008 | A1 |
| 20080075689 | Pierobon et al. | Mar 2008 | A1 |
| 20080089853 | Nguyen-Kim et al. | Apr 2008 | A1 |
| 20080153982 | Lai et al. | Jun 2008 | A1 |
| 20080181948 | Berndl et al. | Jul 2008 | A1 |
| 20080193405 | Mukherjee et al. | Aug 2008 | A1 |
| 20080193544 | Bruck-Scheffler et al. | Aug 2008 | A1 |
| 20080226731 | Vasanthavada et al. | Sep 2008 | A1 |
| 20080233177 | Meconi | Sep 2008 | A1 |
| 20080280999 | Lakshman | Nov 2008 | A1 |
| 20080286221 | Kim et al. | Nov 2008 | A1 |
| 20080299391 | White et al. | Dec 2008 | A1 |
| 20080306233 | Muhrer et al. | Dec 2008 | A1 |
| 20090023754 | Lee et al. | Jan 2009 | A1 |
| 20090053315 | Brough et al. | Feb 2009 | A1 |
| 20090099075 | Barg et al. | Apr 2009 | A1 |
| 20090108241 | Ogura et al. | Apr 2009 | A1 |
| 20090118399 | Benbakoura et al. | May 2009 | A1 |
| 20090148522 | Kowalski et al. | Jun 2009 | A1 |
| 20090161058 | Sherman | Jun 2009 | A1 |
| 20090175952 | Woo et al. | Jul 2009 | A1 |
| 20090220596 | Rosenberg et al. | Sep 2009 | A1 |
| 20090221621 | Sathyan et al. | Sep 2009 | A1 |
| 20090280183 | Lizio et al. | Nov 2009 | A1 |
| 20090285891 | Jung et al. | Nov 2009 | A1 |
| 20090302493 | Kessler et al. | Dec 2009 | A1 |
| 20090311320 | Oury et al. | Dec 2009 | A1 |
| 20090318847 | Sebree et al. | Dec 2009 | A1 |
| 20090321945 | Besling | Dec 2009 | A1 |
| 20100038816 | Ghogh et al. | Feb 2010 | A1 |
| 20100048737 | Wendel et al. | Feb 2010 | A1 |
| 20100074951 | Kim et al. | Mar 2010 | A1 |
| 20100087544 | Kim et al. | Apr 2010 | A1 |
| 20100120970 | Biggs et al. | May 2010 | A1 |
| 20100143459 | Liepold et al. | Jun 2010 | A1 |
| 20100143470 | Kim et al. | Jun 2010 | A1 |
| 20100143590 | Held et al. | Jun 2010 | A1 |
| 20100152299 | Vasanthavada et al. | Jun 2010 | A1 |
| 20100160183 | Xu et al. | Jun 2010 | A1 |
| 20100174040 | Kim et al. | Jul 2010 | A1 |
| 20100209480 | Altenburger et al. | Aug 2010 | A1 |
| 20100209520 | Kubo | Aug 2010 | A1 |
| 20100233447 | Campbell | Sep 2010 | A1 |
| 20100247635 | Rosenberg et al. | Sep 2010 | A1 |
| 20100266859 | Abe et al. | Oct 2010 | A1 |
| 20100272797 | Kim et al. | Oct 2010 | A1 |
| 20100278899 | Sugiura et al. | Nov 2010 | A1 |
| 20100286288 | Langguth et al. | Nov 2010 | A1 |
| 20100291311 | Trouve et al. | Nov 2010 | A1 |
| 20100310644 | Liebmann et al. | Dec 2010 | A1 |
| 20100323090 | Ishizaki et al. | Dec 2010 | A1 |
| 20110002988 | Ishizaki et al. | Jan 2011 | A1 |
| 20110005773 | Dusterhoft et al. | Jan 2011 | A1 |
| 20110032303 | Li | Feb 2011 | A1 |
| 20110052683 | Kim et al. | Mar 2011 | A1 |
| 20110052699 | Funke et al. | Mar 2011 | A1 |
| 20110091563 | Kurasawa et al. | Apr 2011 | A1 |
| 20110111021 | Kim et al. | May 2011 | A1 |
| 20110111022 | Kim et al. | May 2011 | A1 |
| 20110117194 | Kim et al. | May 2011 | A1 |
| 20110123636 | Stayton et al. | May 2011 | A1 |
| 20110144260 | Tanabe et al. | Jun 2011 | A1 |
| 20110201759 | Takahashi | Aug 2011 | A1 |
| 20110242154 | Roberts et al. | Oct 2011 | A1 |
| 20110257289 | Biggs et al. | Oct 2011 | A1 |
| 20110263470 | Qin et al. | Oct 2011 | A1 |
| 20110269913 | Balk et al. | Nov 2011 | A1 |
| 20110274893 | Adolf et al. | Nov 2011 | A1 |
| 20110275775 | Goto et al. | Nov 2011 | A1 |
| 20110287100 | Desset-Brethes et al. | Nov 2011 | A1 |
| 20110305660 | Stayton et al. | Dec 2011 | A1 |
| 20110306632 | Miller et al. | Dec 2011 | A1 |
| 20110312973 | Liepold et al. | Dec 2011 | A1 |
| 20120009223 | Wenguang et al. | Jan 2012 | A1 |
| 20120053248 | Kolter et al. | Mar 2012 | A1 |
| 20120093982 | Tsukioka et al. | Apr 2012 | A1 |
| 20120143039 | Hartwig et al. | Jun 2012 | A1 |
| 20120172574 | Helou et al. | Jul 2012 | A1 |
| 20120183769 | Nasu et al. | Jul 2012 | A1 |
| 20120190724 | Na et al. | Jul 2012 | A1 |
| 20120213827 | Chatterji et al. | Aug 2012 | A1 |
| 20120220550 | Bae et al. | Aug 2012 | A1 |
| 20120232117 | Bae et al. | Sep 2012 | A1 |
| 20120251583 | Rothemund | Oct 2012 | A1 |
| 20120258909 | Liepold et al. | Oct 2012 | A1 |
| 20120282303 | Ito | Nov 2012 | A1 |
| 20120282310 | Lucet-Levannier et al. | Nov 2012 | A1 |
| 20120283670 | Ito | Nov 2012 | A1 |
| 20120323190 | Ito | Dec 2012 | A1 |
| 20120328891 | Suwa et al. | Dec 2012 | A1 |
| 20130005874 | Nakajima et al. | Jan 2013 | A1 |
| 20130011362 | Monahan et al. | Jan 2013 | A1 |
| 20130017245 | Takano | Jan 2013 | A1 |
| 20130034599 | Thaxton et al. | Feb 2013 | A1 |
| 20130040236 | Fukushima et al. | Feb 2013 | A1 |
| 20130085233 | Niitani et al. | Apr 2013 | A1 |
| 20130090480 | Park Choo et al. | Apr 2013 | A1 |
| 20130095168 | Choi et al. | Apr 2013 | A1 |
| 20130129869 | Hafezi et al. | May 2013 | A1 |
| 20130171646 | Park et al. | Jul 2013 | A1 |
| 20130172239 | Gao et al. | Jul 2013 | A1 |
| 20130224859 | Bachelet et al. | Aug 2013 | A1 |
| 20130236551 | Cavazza | Sep 2013 | A1 |
| 20130239339 | Bown et al. | Sep 2013 | A1 |
| 20130243873 | Aversa et al. | Sep 2013 | A1 |
| 20130261019 | Lin et al. | Oct 2013 | A1 |
| 20130274297 | Gatti et al. | Oct 2013 | A1 |
| 20130317096 | Yap et al. | Nov 2013 | A1 |
| 20140018404 | Chen et al. | Jan 2014 | A1 |
| 20140080868 | Ng et al. | Mar 2014 | A1 |
| 20140080869 | Krishnan et al. | Mar 2014 | A1 |
| 20140080886 | Pilot-Matias et al. | Mar 2014 | A1 |
| 20140088152 | Bae et al. | Mar 2014 | A1 |
| 20140128418 | Bae et al. | May 2014 | A1 |
| 20140128827 | Song | May 2014 | A1 |
| 20140155388 | Brzeczko et al. | Jun 2014 | A1 |
| 20140161893 | Shen et al. | Jun 2014 | A1 |
| 20140206742 | Lomuscio et al. | Jul 2014 | A1 |
| 20140235790 | Stayton et al. | Aug 2014 | A1 |
| 20140248350 | Reyes et al. | Sep 2014 | A1 |
| 20140271857 | Nelson et al. | Sep 2014 | A1 |
| 20140303334 | Goto et al. | Oct 2014 | A1 |
| 20150045353 | Comer et al. | Feb 2015 | A1 |
| 20150086624 | Cho et al. | Mar 2015 | A1 |
| 20150104408 | Wakefield et al. | Apr 2015 | A1 |
| 20150118294 | Song et al. | Apr 2015 | A1 |
| 20150132479 | Arfsten et al. | May 2015 | A1 |
| 20150164816 | Jaklenec et al. | Jun 2015 | A1 |
| 20150174250 | Griffiths et al. | Jun 2015 | A1 |
| 20150191132 | Muramoto et al. | Jul 2015 | A1 |
| 20150218125 | Bae et al. | Aug 2015 | A1 |
| 20150232729 | Zhao et al. | Aug 2015 | A1 |
| 20150258093 | Miller et al. | Sep 2015 | A1 |
| 20150283254 | Duvall et al. | Oct 2015 | A1 |
| 20150297526 | Puniya et al. | Oct 2015 | A1 |
| 20150374634 | Koo et al. | Dec 2015 | A1 |
| 20160045446 | Shibata et al. | Feb 2016 | A1 |
| 20160187323 | Farokhzad et al. | Jun 2016 | A1 |
| 20160193246 | Grandfils et al. | Jul 2016 | A1 |
| 20160194368 | Hoge et al. | Jul 2016 | A1 |
| 20160194625 | Hoge et al. | Jul 2016 | A1 |
| 20160220472 | Wang et al. | Aug 2016 | A1 |
| 20160243221 | Hoge et al. | Aug 2016 | A1 |
| 20160243274 | Chisholm et al. | Aug 2016 | A1 |
| 20160244501 | Ellsworth et al. | Aug 2016 | A1 |
| 20160244502 | Bolen et al. | Aug 2016 | A1 |
| 20160250170 | Hsu et al. | Sep 2016 | A1 |
| 20160279251 | Stayton et al. | Sep 2016 | A1 |
| 20160279289 | Chisholm et al. | Sep 2016 | A1 |
| 20160313566 | Le et al. | Oct 2016 | A1 |
| 20160317445 | Saly et al. | Nov 2016 | A1 |
| 20160317647 | Ciaramella et al. | Nov 2016 | A1 |
| 20160375017 | Asmus et al. | Dec 2016 | A1 |
| 20160376333 | Procko et al. | Dec 2016 | A1 |
| 20170002060 | Bolen et al. | Jan 2017 | A1 |
| 20170079932 | Emgenbroich et al. | Mar 2017 | A1 |
| 20170087174 | Beumont et al. | Mar 2017 | A1 |
| 20170105945 | Emgenbroich et al. | Apr 2017 | A1 |
| 20170119690 | Hansen et al. | May 2017 | A1 |
| 20170128380 | Wang | May 2017 | A1 |
| 20170173128 | Hoge et al. | Jun 2017 | A1 |
| 20170211023 | Zhang | Jul 2017 | A1 |
| 20170231989 | Hayashi et al. | Aug 2017 | A1 |
| 20170240765 | Nabuurs et al. | Aug 2017 | A1 |
| 20170247381 | Mao et al. | Aug 2017 | A1 |
| 20170296484 | Kottayil et al. | Oct 2017 | A1 |
| 20170304213 | Shi et al. | Oct 2017 | A1 |
| 20170327463 | Fung et al. | Nov 2017 | A1 |
| 20180031971 | Hustad et al. | Feb 2018 | A1 |
| 20180031972 | Hustad et al. | Feb 2018 | A1 |
| 20180200190 | Dharmadhikari et al. | Jul 2018 | A1 |
| 20180221295 | Hansen et al. | Aug 2018 | A1 |
| 20180221300 | Emgenbroich et al. | Aug 2018 | A1 |
| 20180221402 | Prieve et al. | Aug 2018 | A1 |
| 20180230489 | Kotin | Aug 2018 | A1 |
| 20180237800 | Murthy et al. | Aug 2018 | A1 |
| 20180318365 | Yeung et al. | Nov 2018 | A1 |
| 20180333683 | Liu et al. | Nov 2018 | A1 |
| 20180346797 | Kalgaonkar et al. | Dec 2018 | A1 |
| 20190000765 | Hattori et al. | Jan 2019 | A1 |
| 20190054069 | Chen et al. | Feb 2019 | A1 |
| 20190060425 | Scheel et al. | Feb 2019 | A1 |
| 20190070143 | Boulas et al. | Mar 2019 | A1 |
| 20190070233 | Yeung et al. | Mar 2019 | A1 |
| 20190077923 | Beaume et al. | Mar 2019 | A1 |
| 20190091339 | Miller et al. | Mar 2019 | A1 |
| 20190099381 | Gong et al. | Apr 2019 | A1 |
| 20190125663 | Herry et al. | May 2019 | A1 |
| 20190153471 | Paul et al. | May 2019 | A1 |
| 20190192691 | Barrett et al. | Jun 2019 | A1 |
| 20190194376 | Maejima et al. | Jun 2019 | A1 |
| 20190203030 | Cheong et al. | Jul 2019 | A1 |
| 20190224339 | Paul et al. | Jul 2019 | A1 |
| 20190231712 | Matsumoto et al. | Aug 2019 | A1 |
| 20190247350 | Mizugaki et al. | Aug 2019 | A1 |
| 20190254966 | Bellinger et al. | Aug 2019 | A1 |
| 20190270991 | Foot et al. | Sep 2019 | A1 |
| 20190274346 | Gore et al. | Sep 2019 | A1 |
| 20190365773 | Yokoyama et al. | Dec 2019 | A1 |
| 20190382837 | Spurbeck et al. | Dec 2019 | A1 |
| 20200016092 | Bernardo et al. | Jan 2020 | A1 |
| 20200038390 | Park et al. | Feb 2020 | A1 |
| 20200051813 | Osaki et al. | Feb 2020 | A1 |
| 20200069696 | Liu | Mar 2020 | A1 |
| 20200078463 | Park et al. | Mar 2020 | A1 |
| 20200086616 | Meise et al. | Mar 2020 | A1 |
| 20200123391 | Habets et al. | Apr 2020 | A1 |
| 20200129440 | Baek et al. | Apr 2020 | A1 |
| 20200138072 | Yucel et al. | May 2020 | A1 |
| 20200163962 | Jahagirdar et al. | May 2020 | A1 |
| 20200165630 | Paul et al. | May 2020 | A1 |
| 20200171169 | Duvall et al. | Jun 2020 | A1 |
| 20200188290 | Herrmann et al. | Jun 2020 | A1 |
| 20200197289 | Wang et al. | Jun 2020 | A1 |
| 20200206133 | Alsenz et al. | Jul 2020 | A1 |
| 20200224022 | Gigmes et al. | Jul 2020 | A1 |
| 20200261426 | Park et al. | Aug 2020 | A1 |
| 20200308331 | Kang et al. | Oct 2020 | A1 |
| 20200390752 | Moon et al. | Dec 2020 | A1 |
| 20210069111 | Reineke et al. | Mar 2021 | A1 |
| 20210128479 | Cheng et al. | May 2021 | A1 |
| 20210163985 | Sah et al. | Jun 2021 | A1 |
| 20210196682 | Chen et al. | Jul 2021 | A1 |
| 20210213002 | Natori et al. | Jul 2021 | A1 |
| 20210330599 | Benoit et al. | Oct 2021 | A1 |
| 20210347950 | Kou et al. | Nov 2021 | A1 |
| 20210355454 | Cardinal et al. | Nov 2021 | A1 |
| 20210371470 | Murlidharan et al. | Dec 2021 | A1 |
| 20210373002 | Gopinath et al. | Dec 2021 | A1 |
| 20210387156 | Oschmann et al. | Dec 2021 | A1 |
| 20210387946 | Lindemann et al. | Dec 2021 | A1 |
| 20220008346 | Wilson et al. | Jan 2022 | A1 |
| 20220016098 | Cho et al. | Jan 2022 | A1 |
| 20220016271 | Farokhzad et al. | Jan 2022 | A1 |
| 20220031607 | Cho et al. | Feb 2022 | A1 |
| 20220143062 | Kahvejian et al. | May 2022 | A1 |
| 20220175812 | Duong et al. | Jun 2022 | A1 |
| 20220233514 | Choi et al. | Jul 2022 | A1 |
| 20220233580 | Takeshita et al. | Jul 2022 | A1 |
| 20220243225 | Mathur et al. | Aug 2022 | A1 |
| 20220291432 | Donal | Sep 2022 | A1 |
| 20230059080 | Lee et al. | Feb 2023 | A1 |
| 20230067461 | Lee et al. | Mar 2023 | A1 |
| 20230092431 | Isabella et al. | Mar 2023 | A1 |
| 20230218536 | Solomun et al. | Jul 2023 | A1 |
| 20230227687 | Li et al. | Jul 2023 | A1 |
| 20230310621 | Grandfils et al. | Oct 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 1323840 | Nov 2001 | CN |
| 1328106 | Dec 2001 | CN |
| 1806901 | Jul 2006 | CN |
| 1813683 | Aug 2006 | CN |
| 1896112 | Jan 2007 | CN |
| 101444513 | Jun 2009 | CN |
| 101643412 | Feb 2010 | CN |
| 101735383 | Jun 2010 | CN |
| 102030871 | Apr 2011 | CN |
| 102250278 | Nov 2011 | CN |
| 102949342 | Mar 2013 | CN |
| 103113509 | May 2013 | CN |
| 103255174 | Aug 2013 | CN |
| 103319668 | Sep 2013 | CN |
| 103333283 | Oct 2013 | CN |
| 103536972 | Jan 2014 | CN |
| 103755870 | Apr 2014 | CN |
| 103976972 | Aug 2014 | CN |
| 104479064 | Apr 2015 | CN |
| 104772051 | Jul 2015 | CN |
| 104784155 | Jul 2015 | CN |
| 104922078 | Sep 2015 | CN |
| 104971073 | Oct 2015 | CN |
| 105504923 | Apr 2016 | CN |
| 105833272 | Aug 2016 | CN |
| 105833287 | Aug 2016 | CN |
| 105949365 | Sep 2016 | CN |
| 106117580 | Nov 2016 | CN |
| 106236785 | Dec 2016 | CN |
| 106478904 | Mar 2017 | CN |
| 106811998 | Jun 2017 | CN |
| 107173546 | Sep 2017 | CN |
| 107596368 | Jan 2018 | CN |
| 115714187 | Feb 2023 | CN |
| 2446449 | Apr 1975 | DE |
| 0217137 | Apr 1987 | EP |
| 0587333 | Mar 1994 | EP |
| 0597577 | May 1994 | EP |
| 0945148 | Sep 1999 | EP |
| 1008634 | Jun 2000 | EP |
| 1284489 | Aug 1972 | GB |
| 1314285 | Apr 1973 | GB |
| 1324087 | Jul 1973 | GB |
| 2012MU01581 | Jan 2014 | IN |
| 2014KO01127 | May 2016 | IN |
| 201611026597 | Mar 2018 | IN |
| 201921005566 | Aug 2020 | IN |
| S5156886 | May 1976 | JP |
| S51100129 | Sep 1976 | JP |
| H01229014 | Sep 1989 | JP |
| 2003345095 | Dec 2003 | JP |
| 2008274217 | Nov 2008 | JP |
| 2008274218 | Nov 2008 | JP |
| 2008274219 | Nov 2008 | JP |
| 2009016258 | Jan 2009 | JP |
| 2010111781 | May 2010 | JP |
| 2011074250 | Apr 2011 | JP |
| 2011207963 | Oct 2011 | JP |
| 2013029832 | Feb 2013 | JP |
| 2013114184 | Jun 2013 | JP |
| 2013237821 | Nov 2013 | JP |
| 2016065115 | Apr 2016 | JP |
| 2016126154 | Jul 2016 | JP |
| 2017058405 | Mar 2017 | JP |
| 2018154752 | Oct 2018 | JP |
| 2018174919 | Nov 2018 | JP |
| 2018203987 | Dec 2018 | JP |
| 2019127444 | Aug 2019 | JP |
| 2020074704 | May 2020 | JP |
| 2022057447 | Apr 2022 | JP |
| 2022076360 | May 2022 | JP |
| 2022117407 | Aug 2022 | JP |
| 830000972 | Apr 1983 | KR |
| 20020016069 | Mar 2002 | KR |
| 20030078118 | Oct 2003 | KR |
| 20050023239 | Mar 2005 | KR |
| 20080002313 | Jan 2008 | KR |
| 20080008769 | Jan 2008 | KR |
| 100867639 | Nov 2008 | KR |
| 20080097787 | Nov 2008 | KR |
| 20090114190 | Nov 2009 | KR |
| 100994148 | Nov 2010 | KR |
| 20110043347 | Apr 2011 | KR |
| 20110117758 | Oct 2011 | KR |
| 20110119542 | Nov 2011 | KR |
| 20110135018 | Dec 2011 | KR |
| 20120047345 | May 2012 | KR |
| 20120134329 | Dec 2012 | KR |
| 20120134605 | Dec 2012 | KR |
| 20130010708 | Jan 2013 | KR |
| 20130013157 | Feb 2013 | KR |
| 20130027822 | Mar 2013 | KR |
| 20130030907 | Mar 2013 | KR |
| 101312286 | Sep 2013 | KR |
| 20140095767 | Aug 2014 | KR |
| 20140105941 | Sep 2014 | KR |
| 101458468 | Nov 2014 | KR |
| 20140130579 | Nov 2014 | KR |
| 20150105043 | Sep 2015 | KR |
| 20170076494 | Jul 2017 | KR |
| 101827744 | Feb 2018 | KR |
| 20180029147 | Mar 2018 | KR |
| 101850629 | Apr 2018 | KR |
| 20180099263 | Sep 2018 | KR |
| 101923028 | Nov 2018 | KR |
| 101943270 | Jan 2019 | KR |
| 20190111448 | Oct 2019 | KR |
| 102107332 | May 2020 | KR |
| 102157964 | Sep 2020 | KR |
| 102207353 | Jan 2021 | KR |
| 102207354 | Jan 2021 | KR |
| 102212503 | Feb 2021 | KR |
| 102212504 | Feb 2021 | KR |
| 102212505 | Feb 2021 | KR |
| 20210122720 | Oct 2021 | KR |
| 440443 | Aug 2023 | PL |
| 2582704 | Apr 2016 | RU |
| 201204713 | Feb 2012 | TW |
| 201404805 | Feb 2014 | TW |
| 1991013145 | Sep 1991 | WO |
| 1998051749 | Nov 1998 | WO |
| 03090780 | Jun 2003 | WO |
| 2004096422 | Nov 2004 | WO |
| 2007060462 | May 2007 | WO |
| 2008005543 | Jan 2008 | WO |
| 2007078765 | Apr 2008 | WO |
| 2008050987 | May 2008 | WO |
| 2009038340 | Mar 2009 | WO |
| 2009088220 | Jul 2009 | WO |
| 2009103735 | Aug 2009 | WO |
| 2009125987 | Oct 2009 | WO |
| 2009127922 | Oct 2009 | WO |
| 2009134053 | Nov 2009 | WO |
| 2009134076 | Nov 2009 | WO |
| 2009141159 | Nov 2009 | WO |
| 2009142421 | Nov 2009 | WO |
| 2009151295 | Dec 2009 | WO |
| 2010008203 | Jan 2010 | WO |
| 2010008244 | Jan 2010 | WO |
| 2011025167 | Mar 2011 | WO |
| 2011025267 | Mar 2011 | WO |
| 2011025269 | Mar 2011 | WO |
| 2011025270 | Mar 2011 | WO |
| 2011025271 | Mar 2011 | WO |
| 2011154331 | Dec 2011 | WO |
| 2012101235 | Aug 2012 | WO |
| 2012061719 | Aug 2012 | WO |
| 2012108631 | Aug 2012 | WO |
| 2012119997 | Sep 2012 | WO |
| 2012138013 | Oct 2012 | WO |
| 2012140415 | Oct 2012 | WO |
| 2012156058 | Nov 2012 | WO |
| 2012156059 | Nov 2012 | WO |
| 2012158610 | Nov 2012 | WO |
| 2013135853 | Sep 2013 | WO |
| 2014109308 | Jul 2014 | WO |
| 2015089419 | Jun 2015 | WO |
| 2015134787 | Sep 2015 | WO |
| 2016025747 | Feb 2016 | WO |
| 2016164762 | Oct 2016 | WO |
| 2016195153 | Dec 2016 | WO |
| 2017184768 | Oct 2017 | WO |
| 2017176040 | Oct 2017 | WO |
| 2017210666 | Dec 2017 | WO |
| 2018112555 | Jun 2018 | WO |
| 2018190355 | Oct 2018 | WO |
| 2019027767 | Feb 2019 | WO |
| 2019088662 | May 2019 | WO |
| 2019126627 | Jun 2019 | WO |
| 2019152957 | Aug 2019 | WO |
| 2019199133 | Oct 2019 | WO |
| 2019220088 | Nov 2019 | WO |
| 2020017808 | Jan 2020 | WO |
| 2020051507 | Mar 2020 | WO |
| 2020080875 | Apr 2020 | WO |
| 2020106916 | May 2020 | WO |
| 2020247382 | Dec 2020 | WO |
| 2021007382 | Jan 2021 | WO |
| 2021076977 | Apr 2021 | WO |
| 2021091188 | May 2021 | WO |
| 2021125797 | Jun 2021 | WO |
| 2021194253 | Sep 2021 | WO |
| 2021255262 | Dec 2021 | WO |
| 2022091971 | May 2022 | WO |
| 2022120194 | Jun 2022 | WO |
| 2022129097 | Jun 2022 | WO |
| 2022139687 | Jun 2022 | WO |
| 2022245307 | Nov 2022 | WO |
| 2022266119 | Dec 2022 | WO |
| 2023023055 | Feb 2023 | WO |
| 2023107574 | Jun 2023 | WO |
| 2023193244 | Oct 2023 | WO |
| 2023239921 | Dec 2023 | WO |
| 2023239922 | Dec 2023 | WO |
| Entry |
|---|
| Conesa, Ana et al., “A survey of best practices for RNA-seq data analysis.” Genome Biology, Jan. 26, 2016, vol. 17, No. 13; doi:10.1186/s13059-016-0881-8. |
| PCT Written Opinion for PCT/US22/23902, dated Sep. 9, 2022. |
| U.S. Appl. No. 18/475,879, Pending. |
| U.S. Appl. No. 18/332,065, Pending. |
| U.S. Appl. No. 17/542,055, Pending. |
| U.S. Appl. No. 18/332101, Pending. |
| Cheng et al. “Polycation Architecture Affects Complexation and Delivery of Short Antisense Oligonucleotides: Micelleplexes Outperform Polyplexes.” Biomacromolecules 2022 23 (8), 3257-3271, DOI: 10.1021/acs.biomac.2c00338. |
| Sprouse et al. “Tuning Cationic Block Copolymer Micelle Size by pH and lonic Strength.” Biomacromolecules 2016, 17, 9, 2849-2859. DOI:10.1021/acs.biomac.6b00654. |
| Convertine et al. “Development of a novel endosomolytic diblock copolymer for siRNA delivery.” Journal of controlled release : official journal of the Controlled Release Society vol. 133,3 (2009): 221-9. DOI: 10.1016/j.jconrel.2008.10.004. |
| Convertine et al. “pH-responsive polymeric micelle carriers for siRNA drugs.” Biomacromolecules vol. 11,11 (2010): 2904-11. doi: 10.1021/bm100652w. |
| Lauber et al. “pH- and Thermoresponsive Self-Assembly of Cationic Triblock Copolymers with Controlled Dynamics.” Macromolecules 2017, 50, 1, 416-423. doi: 10.1021/acs.macromol.6b02201. |
| Haridharan et al. “Exploration of Novel Pyrene Labeled Amphiphilic Block Copolymers: Synthesis Via ATRP, Characterization and Properties.” Journal of Macromolecular Science, Part A, vol. 47, No. 9, Jul. 2010, pp. 918-926, doi:10.1080/10601325.2010.501681. |
| Kanth et al. “Recent advances in development of poly (dimethylaminoethyl methacrylate) antimicrobial polymers, European Polymer Journal.” vol. 163, 2022, doi: 10.1016/j.eurpolymj.2021.110930. |
| Manganiello et al. “Diblock copolymers with tunable pH transitions for gene delivery.” Biomaterials vol. 33,7 (2012): 2301-9. doi: 10.1016/j.biomaterials.2011.11.019. |
| Muehlebach et al. “Synthesis of Well-Defined Macromonomers and Comb Copolymers from Polymers Made by Atom Transfer Radical Polymerization.” J Polym Sci Part A: Polym Chem. vol. 41,21 (2003): 3425-3439, doi: 10.1002/pola. 10940. |
| Pegg et al. “Solubilisation of oils in aqueous solutions of a random cationic copolymer.” Journal of colloid and interface science vol. 502 (2017): 210-218. doi:10.1016/j.jcis.2017.04.093. |
| Grimme et al. “Polycation Architecture Affects Complexation and Delivery of Short Antisense Oligonucleotides: Micelleplexes Outperform Polyplexes.” Biomacromolecules 2022, 23, 8, 3257-3271, doi: 10.1021/acs.biomac.2c00338. |
| Number | Date | Country | |
|---|---|---|---|
| 20220333097 A1 | Oct 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63172069 | Apr 2021 | US |
